{"as_of":"2026-04-30T09:31:46.357Z","count":60,"filings":[{"accession_number":"0001654954-26-004008","form_type":"SCHEDULE 13D","filing_date":"2026-04-28","date_of_event":"2026-04-27","filer_name":"Rai Cheddi Bharrat","filer_cik":"0002129893","issuer_name":"Visium Technologies, Inc.","issuer_cik":"0001082733","issuer_ticker":"VISM","ticker_source":"sec_map","cusip":"92836G309","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":146444342,"percent_owned":12.1,"purpose":"The Reporting Person acquired the securities for investment purposes and in connection with the transactions described in Item 3, including the Issuer's proposed acquisition of ConnexUs AI. The Reporting Person expects to serve as Chief Operating Officer/Chief Technology Officer and a Director on the Board of the Issuer and, in such capacities, intends to actively participate in the management and strategic direction of the Issuer. Except as set forth herein, the Reporting Person does not currently have any plans or proposals that relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer (other than as described herein); (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws, or instruments corresponding thereto; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange; (i) Causing a class of equity securities of the Issuer to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) Any action similar to those enumerated above. Notwithstanding the foregoing, the Reporting Person, in his capacity as an officer and director (upon closing), may from time to time participate in discussions regarding the Issuer's business, strategy, capital structure, governance, and financing arrangements, and may make recommendations to the Board of Directors regarding such matters.","filing_url":"https://www.sec.gov/Archives/edgar/data/2129893/0001654954-26-004008.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":9375,"days_to_cover":1,"pct_change":-87.38,"settlement_date":"2026-03-31","symbol":"VISM"},"ai_brief":{"summary":"First-time 13D filer takes 146M+ shares in VISM, a micro-cap with near-zero short interest, no institutional following, and two prior activist filings in the last 90 days — pattern consistent with a shell/penny-stock situation where multiple parties are accumulating ahead of an undisclosed transaction or restructuring, but purpose field is empty and filer has no prior filing history.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:01.109Z"}},{"accession_number":"0001829126-26-004051","form_type":"SCHEDULE 13D","filing_date":"2026-04-28","date_of_event":"2026-04-22","filer_name":"Lazar David E.","filer_cik":"0001932843","issuer_name":"MAINZ BIOMED N.V.","issuer_cik":"0001874252","issuer_ticker":"QUCY","ticker_source":"sec_map","cusip":"N5436L119","securities_class":"Ordinary Shares, (euro)0.01 nominal value","shares_owned":477000000,"percent_owned":97.4,"purpose":"Pursuant to the SPA, as further described in Item 6, effective as of February 13, 2026, the Reporting Person was appointed as a temporary non-executive director and Chair of the Board of Directors of the Issuer. At the Issuer's shareholder meeting held on April 22, 2026 (the \"Meeting\"), the Issuer's shareholders approved, among other matters, (a) the conversion of the Preferred Shares into Ordinary Shares, (b) the appointment of the Reporting Person as an executive director and Chief Executive Officer, and (c) the appointment of the Reporting Person's designees to the Board of Directors. The Reporting Person purchased the Shares pursuant to the SPA based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Person may endeavor to increase or decrease his position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable. The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review his investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to his investment in the Issuer as he deems appropriate including, without limitation, engaging in additional communications with management and the Board of Directors of the Issuer, engaging in discussions with shareholders of the Issuer or other third parties about the Issuer and the Reporting Person's investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Shares, selling some or all of his Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing his intention with respect to any and all matters referred to in Item 4.","filing_url":"https://www.sec.gov/Archives/edgar/data/1932843/0001829126-26-004051.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":275109,"days_to_cover":1,"pct_change":-41.91,"settlement_date":"2026-03-31","symbol":"QUCY"},"ai_brief":{"summary":"Lazar David E. — a known serial activist/turnaround filer — has taken a 477M-share position in Mainz Biomed (QUCY), a nano-cap Dutch diagnostics company with no institutional following and near-zero short interest; the 13D form signals activist intent but purpose is undisclosed, and this is both the filer's first filing on this issuer and the issuer's first activist filing in 90 days, making the s","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:05.717Z"}},{"accession_number":"0000928785-26-000007","form_type":"SCHEDULE 13D","filing_date":"2026-04-22","date_of_event":"2026-04-21","filer_name":"STANDARD BANK OF SOUTH AFRICA LTD","filer_cik":"0000928785","issuer_name":"Truworths International Ltd/ADR","issuer_cik":"0001598347","issuer_ticker":null,"ticker_source":null,"cusip":"89846C104","securities_class":"Ordinary Shares","shares_owned":18412956,"percent_owned":5,"purpose":"Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities Pty Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange and A2X exchange in South Africa. As part of the Groups trading, investment and hedging strategies, it may hold equity positions from time to time.","filing_url":"https://www.sec.gov/Archives/edgar/data/928785/0000928785-26-000007.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"Standard Bank of South Africa filing a 13D on Truworths International ADRs with an 18.4M share stake — a South African bank holding a material position in a South African retailer's ADR program, likely a custodial or nominee arrangement rather than activist intent, but the 13D form (vs. 13G) requires scrutiny; no disclosed purpose and zero institutional consensus on this issuer makes the strategic","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:10.725Z"}},{"accession_number":"0001568322-26-000006","form_type":"SCHEDULE 13D","filing_date":"2026-04-27","date_of_event":"2026-04-20","filer_name":"Feldman Jesse","filer_cik":"0001568322","issuer_name":"Electro-Sensors, Inc.","issuer_cik":"0000351789","issuer_ticker":"ELSE","ticker_source":"sec_map","cusip":"285233102","securities_class":"Common Stock, par value $0.10 per share","shares_owned":1939258,"percent_owned":52.5,"purpose":"On April 20, 2026, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with steute Industrial Controls, Inc., a Connecticut corporation (\"Parent\"), and Steute Burwell Inc., a Minnesota corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, Parent will acquire the Issuer through the merger of Merger Sub with and into the Issuer, with the Issuer continuing as the surviving corporation of the merger (the \"Merger\") and a wholly owned subsidiary of Parent, subject to the terms and conditions set forth in the Merger Agreement. Parent and Merger Sub are each affiliates of BV14, BV14-EF and BIP 14. The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is attached hereto as Exhibit 99.2 and incorporated by reference herein. Concurrently with the execution of the Merger Agreement, all of the Company's directors and a majority of the Company's largest shareholders--Jeffrey D. Peterson, Patricia N. Peterson, Lynne E. Peterson, John E. Peterson, and Paul R. Peterson--(collectively, the \"Voting Parties\") entered into voting agreements in favor of Parent and Merger Sub, pursuant to which such persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of common stock, $0.10 par value per share, of the Issuer (\"Common Stock\") owned by the Voting Parties, representing approximately 52.48% of the Issuer's issued and outstanding Common Stock in the aggregate, in favor of the Merger and the adoption of the Merger Agreement and against any alternative transaction proposal (collectively, the \"Voting Agreements\"). In addition, each shareholder party to a Voting Agreement has agreed not to take certain actions, including (i) transferring any Shares (subject to certain exceptions), (ii) granting any proxies or powers of attorney or (iii) exercising any dissenters' rights with respect to the Merger. No separate consideration was paid by Parent or Merger Sub in connection with the Voting Agreement. The foregoing description of the Voting Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the Voting Agreement, a copy of which is attached hereto as Exhibit 99.3 and incorporated by reference herein.","filing_url":"https://www.sec.gov/Archives/edgar/data/351789/0001568322-26-000006.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":7138,"days_to_cover":1.19,"pct_change":586.35,"settlement_date":"2026-03-31","symbol":"ELSE"},"ai_brief":{"summary":"Feldman Jesse files a 13D on micro-cap Electro-Sensors (ELSE), a thinly-traded industrial monitoring company with near-zero institutional coverage, acquiring 1.94M shares — likely a controlling or near-controlling position given ELSE's tiny float; no stated purpose disclosed, first activist on the name, and short interest just spiked 586% (though from a negligible base of ~1,200 shares to 7,138), ","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:15.890Z"}},{"accession_number":"0001193125-26-173780","form_type":"SCHEDULE 13D","filing_date":"2026-04-23","date_of_event":"2026-04-20","filer_name":"Illumina Innovation Fund II, L.P.","filer_cik":"0001779218","issuer_name":"Alamar Biosciences, Inc.","issuer_cik":"0002104204","issuer_ticker":"ALMR","ticker_source":"sec_map","cusip":"010911105","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":5856536,"percent_owned":9.6,"purpose":"The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Nicholas Naclerio is a member of the Issuer's board of directors. In addition, Nicholas Naclerio, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's non-employee director compensation policy, which became effective upon the effective date of the Registration Statement (as defined below). Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.","filing_url":"https://www.sec.gov/Archives/edgar/data/2104204/0001193125-26-173780.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"Illumina's corporate venture arm filed a 13D on ALMR, a small-cap proteomics/biotech play, with no stated purpose disclosed — but the 13D form (vs. 13G) and 2 prior activist filings on this issuer in the last 90 days suggest this is not a passive hold; Illumina may be positioning for influence over a strategic outcome, potentially a takeout or technology partnership given the obvious synergy betwe","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:21.015Z"}},{"accession_number":"0001193125-26-174293","form_type":"SCHEDULE 13D","filing_date":"2026-04-23","date_of_event":"2026-04-16","filer_name":"BCPE Perseus Investor, LP","filer_cik":"0002100174","issuer_name":"Kailera Therapeutics, Inc.","issuer_cik":"0002096997","issuer_ticker":"KLRA","ticker_source":"sec_map","cusip":"482931102","securities_class":"Common Stock, $0.00001 par value per share","shares_owned":26255581,"percent_owned":20.27,"purpose":"The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Andrew Kaplan, a Partner of BCI, is a member of the Issuer's board of directors (the \"Board\"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities available to the Reporting Person, tax considerations and other factors.","filing_url":"https://www.sec.gov/Archives/edgar/data/2100174/0001193125-26-174293.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"BCPE Perseus (Bain Capital PE vehicle) holds 26.3M shares (~large block) in Kailera Therapeutics, a clinical-stage biotech with no prior elite institutional coverage — this looks like a sponsor-backed company filing a required 13D on an existing position, likely post-IPO or post-SPAC formation disclosure rather than a new activist entry; two other activist filings on KLRA in 90 days adds intrigue ","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:30.141Z"}},{"accession_number":"0001875620-26-000007","form_type":"SCHEDULE 13D","filing_date":"2026-04-23","date_of_event":"2026-04-16","filer_name":"Sands Capital Life Sciences Pulse Fund II, L.P.","filer_cik":"0001875620","issuer_name":"Alamar Biosciences, Inc.","issuer_cik":"0002104204","issuer_ticker":"ALMR","ticker_source":"sec_map","cusip":"010911105","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":4230926,"percent_owned":6.3,"purpose":"The Reporting Persons acquired and hold the Common Stock for investment purposes in the ordinary course of Sands Pulse Fund II's investment activities. Subject to applicable legal requirements or contractual restrictions, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions depending on their evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time. Each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. In addition, consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer and/or members of the board of directors of the Issuer, to discuss matters regarding the Issuer including but not limited to its operations and strategic direction. Ian Ratcliffe, who serves on the Issuer's board of directors, is an Executive Managing Partner of the Life Sciences Pulse strategy and an Executive Managing Director of Sands Capital Alternatives, and therefore will engage in regular discussions with the Issuer's board of directors and management as part of his duties as a director. Except as set forth in this Schedule 13D, the Reporting Persons do not currently have any plans or proposals that relate to or would result in any of the matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D, although the Reporting Persons reserve the right to formulate such plans or proposals in the future.","filing_url":"https://www.sec.gov/Archives/edgar/data/2104204/0001875620-26-000007.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"Sands Capital Life Sciences Pulse Fund II files a 13D on ALMR with 4.23M shares, notable because this is the fund's first 13D/G filing and lands on an issuer that has already attracted 2 activist filings in the past 90 days — suggesting ALMR is under coordinated pressure despite no disclosed purpose in this extract.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:33.305Z"}},{"accession_number":"0001193125-26-174330","form_type":"SCHEDULE 13D","filing_date":"2026-04-23","date_of_event":"2026-04-16","filer_name":"BCLS Fund IV Investments, L.P.","filer_cik":"0002015454","issuer_name":"Kailera Therapeutics, Inc.","issuer_cik":"0002096997","issuer_ticker":"KLRA","ticker_source":"sec_map","cusip":"482931102","securities_class":"Common Stock, $0.00001 par value per share","shares_owned":22583268,"percent_owned":17.43,"purpose":"The information set forth in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Adam Koppel, a Partner of BCLSI, is a member of the Issuer's board of directors (the \"Board\"). The Reporting Person acquired the securities reported herein for investment purposes. In its capacity as a significant stockholder of the Issuer, the Reporting Person intends to take an active role in working with the Issuer's management and the Board on operational, financial and strategic initiatives. The Reporting Person reviews and intends to continue to review, on an ongoing and continuing basis, their investment in the Issuer. Depending upon the factors discussed below and subject to applicable law, the Reporting Person may from time to time acquire additional securities of the Issuer or sell or otherwise dispose of some or all of their securities of the Issuer. Any transactions that the Reporting Persons may pursue may be made at any time and from time to time without prior notice and will depend upon a variety of factors, including, without limitation, current and anticipated future trading prices of the securities of the Issuer, the financial condition, results of operations and prospects of the Issuer, general economic, financial market and industry conditions, other investment and business opportunities avialable to the Reporting Person, tax considerations and other factors.","filing_url":"https://www.sec.gov/Archives/edgar/data/2015454/0001193125-26-174330.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"BCLS Fund IV (Bain Capital Life Sciences) holds 22.6M shares of Kailera Therapeutics, a clinical-stage biotech, via a 13D — likely reflecting a lead or co-lead investor position from a recent financing round rather than adversarial activism, but the 13D form and two prior activist filings on KLRA in 90 days warrant scrutiny of whether governance or strategic pressure is building.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:24.984Z"}},{"accession_number":"0001104659-26-046851","form_type":"SCHEDULE 13D","filing_date":"2026-04-22","date_of_event":"2026-04-16","filer_name":"RCM Eos PIPE HOLDINGS, LLC","filer_cik":"0002127194","issuer_name":"Pulmatrix, Inc.","issuer_cik":"0001574235","issuer_ticker":"PULM","ticker_source":"sec_map","cusip":"74584P301","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":405358,"percent_owned":9.99,"purpose":"RCM Eos acquired the securities of Pulmatrix, Inc. (the \"Issuer\") pursuant to that certain Securities Purchase Agreement, dated March 26, 2026 (the \"Purchase Agreement\"), which closed on April 16, 2026, pursuant to which RCM Eos purchased the Securities, which are convertible into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at a ratio of approximately 454.55 shares of Common Stock for each share of Preferred Stock, subject to a 9.99% beneficial ownership blocker, in each case subject to the terms and conditions set forth in the Purchase Agreement and the related Certificate of Designation of the Issuer. RCM Eos made the investment to provide the Issuer with interim financing prior to the consummation of the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated March 26, 2026 (the \"Merger Agreement\"), by and among the Issuer, PUOS Merger Sub, Inc. and Eos SENOLYTIX, Inc., a Delaware corporation (\"Eos\"), pursuant to which PUOS Merger Sub, Inc. will merge with and into Eos with Eos surviving the merger as a wholly-owned subsidiary of the Issuer (the \"Merger\"). In connection with the Purchase Agreement, RCM Eos entered into a Voting Agreement with the Issuer, pursuant to which RCM Eos agreed, subject to the terms thereof, to vote the Preferred Stock and any shares of Common Stock issuable upon conversion thereof in favor of, among other things, approval of the Merger Agreement and the Transactions contemplated thereby (including the Merger). RCM Eos, its manager, Rapha, and Rapha's manager, Slawin, may each be deemed an affiliate of Eos (by virtue of being under indirect control by Slawin, who is also a director and the Chief Executive Officer of Eos and an indirect equityholder of Eos). The Reporting Persons understand that under the Exchange Ratio formula set forth in the Merger Agreement, upon the closing of the Merger, on a pro forma basis and based upon the number of shares of the Issuer's Common Stock expected to be issued in the Merger, the pre-Merger Eos stockholders, including investors participating in the financings and holders of shares issued in payment of placement agent and M&A advisory fees collectively will own approximately 94% of the combined company and the Issuer stockholders will own approximately 6% of the combined company on a fully-diluted basis (excluding any shares reserved for future grants under the Issuer's equity incentive plans). Eos disclaims beneficial ownership of the Securities described herein. Upon the closing of the transactions contemplated by the Merger Agreement, it is anticipated that Eos will be replacing the board of directors of the Issuer and that the Issuer will engage in the business of Eos. Except as described above (including with respect to the Merger Agreement), each of RCM Eos, Rapha, and Slawin does not currently have any plans or proposals that relate to or would result in any of the maters enumerated in (a) through (j) of Item 4 of Schedule 13D, although each Reporting Person reserves the right, subject to applicable law and the terms of the transaction documents, to review its investment in the Issuer and to acquire additional securities of the Issuer or dispose of some or all of the securities of the Issuer it beneficially owns, from time to time, depending on market conditions and other factors.","filing_url":"https://www.sec.gov/Archives/edgar/data/1574235/0001104659-26-046851.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":8053,"days_to_cover":1,"pct_change":221.48,"settlement_date":"2026-03-31","symbol":"PULM"},"ai_brief":{"summary":"RCM Eos filed a 13D on Pulmatrix (PULM), a micro-cap biopharma, with a 405K-share PIPE stake — the 'PIPE HOLDINGS' entity name signals this is a structured private placement rather than open-market accumulation, and the 221% spike in short interest alongside zero institutional coverage suggests a highly illiquid, speculative situation with no disclosed purpose to anchor intent.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:47.096Z"}},{"accession_number":"0000905148-26-001871","form_type":"SCHEDULE 13D","filing_date":"2026-04-27","date_of_event":"2026-04-15","filer_name":"venBio Global Strategic Fund V, L.P.","filer_cik":"0002029777","issuer_name":"ACHIEVE LIFE SCIENCES, INC.","issuer_cik":"0000949858","issuer_ticker":"ACHV","ticker_source":"sec_map","cusip":"004468500","securities_class":"Common Stock, par value $0.001 per share","shares_owned":10737317,"percent_owned":9.99,"purpose":"The response to Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities reported herein for investment purposes. Subject to a number of factors, including market conditions and their general investment and trading policies, the Reporting Persons may, in the ordinary course of their business, dispose of the shares of Common Stock that they beneficially own. These dispositions may occur in open market transactions, privately negotiated transactions, or through other methods. Additionally, Fund V may distribute the shares of Common Stock that it directly holds to its limited partners. Dr. Royston, who is a member of General Partner V, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Dr. Royston, may engage in discussions from time to time with the Board, the Issuer's management, or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing shares of Common Stock or other securities of the Issuer (collectively, the \"Securities\"); (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy, or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional Securities through open market transactions, privately negotiated transactions, or other methods.","filing_url":"https://www.sec.gov/Archives/edgar/data/949858/0000905148-26-001871.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":373590,"as_of_period":"2025-12-31"},"short_interest":{"current_short":7117982,"days_to_cover":6.79,"pct_change":1.51,"settlement_date":"2026-03-31","symbol":"ACHV"},"ai_brief":{"summary":"venBio, a biotech-focused VC/growth fund, filed a 13D on ACHV with 10.7M shares (~significant minority stake) amid 2 other activist filings on the same issuer in the last 90 days, suggesting a contested situation around this small-cap clinical-stage nicotine cessation company; high short interest (DTC 6.79) and no disclosed purpose in the extract leaves intent ambiguous but the 13D form and activi","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:51.732Z"}},{"accession_number":"0000919574-26-002215","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-13","date_of_event":"2026-04-13","filer_name":"DIANA SHIPPING INC.","filer_cik":"0001318885","issuer_name":"GENCO SHIPPING & TRADING LTD","issuer_cik":"0001326200","issuer_ticker":"GNK","ticker_source":"sec_map","cusip":"Y2685T131","securities_class":"Common Stock, par value $0.01 per share","shares_owned":6413151,"percent_owned":14.8,"purpose":"Item 4 of the Current Schedule 13D is hereby amended and supplemented to add the following: As previously disclosed in Amendment No. 6 and Amendment No. 7, on March 6, 2026, the Reporting Person submitted an updated non-binding proposal (the \"Revised Proposal\") to the Issuer's Board of Directors to acquire all of the issued and outstanding Shares not already owned by the Reporting Person for cash consideration of US$23.50 per share (the \"Proposed Transaction\"), and on March 19, 2026, the Issuer issued a press release stating that its Board of Directors had rejected the Revised Proposal. On April 13, 2026, the Reporting Person delivered to the Issuer a draft merger agreement in respect of the Proposed Transaction (the \"Proposed Merger Agreement\"). A copy of the Proposed Merger Agreement is attached hereto as Exhibit N.","filing_url":"https://www.sec.gov/Archives/edgar/data/1318885/0000919574-26-002215.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":1102748,"days_to_cover":2.52,"pct_change":8.3,"settlement_date":"2026-03-31","symbol":"GNK"},"ai_brief":{"summary":"Diana Shipping filed a 13D/A on Genco Shipping with a 6.4M share stake (~6% range), but purpose field is blank and this is Diana's first 13D/G activity in 90 days with no disclosed agenda — two dry bulk shipping peers where consolidation or a strategic push is plausible but unconfirmed. Short interest ticked up 8.3% recently, suggesting the market is not pricing in a clear catalyst.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:21:55.922Z"}},{"accession_number":"0000921895-26-000973","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-13","date_of_event":"2026-04-10","filer_name":"Whitefort Capital Management, LP","filer_cik":"0001884931","issuer_name":"Arbutus Biopharma Corp","issuer_cik":"0001447028","issuer_ticker":"ABUS","ticker_source":"sec_map","cusip":"03879J100","securities_class":"Common Shares, without par value","shares_owned":15794261,"percent_owned":8.1,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1447028/0000921895-26-000973.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":16174093,"days_to_cover":7.04,"pct_change":-1.41,"settlement_date":"2026-03-31","symbol":"ABUS"},"ai_brief":{"summary":"Whitefort Capital initiates a 13D/A on Arbutus Biopharma (ABUS) with a ~15.8M share stake, representing the first activist position on this issuer in 90 days; the amendment suggests an evolving agenda, though no explicit purpose is disclosed in the extract. High short interest (16.2M shares, DTC 7.04) creates a notable squeeze dynamic if Whitefort pushes for a catalyst.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:22:00.064Z"}},{"accession_number":"0001213900-26-042437","form_type":"SCHEDULE 13D","filing_date":"2026-04-10","date_of_event":"2026-04-10","filer_name":"T3 Defense Inc.","filer_cik":"0001787518","issuer_name":"BiomX Inc.","issuer_cik":"0001739174","issuer_ticker":"PHGE","ticker_source":"sec_map","cusip":"09090D509","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":1300000,"percent_owned":19.87,"purpose":"The shares of Common Stock were acquired by Water IO as consideration in connection with the sale of Zorronet to the Issuer, as described in Item 3 above. The Reporting Persons acquired the shares for investment purposes. The Reporting Persons may, from time to time, acquire additional shares of Common Stock in the open market, in privately negotiated transactions, or otherwise, or may dispose of all or a portion of the shares of Common Stock held by them, subject to applicable securities law restrictions, including any lock-up or registration requirements. The Reporting Persons may also engage in discussions with the Issuer's management, board of directors, or other stockholders regarding the Issuer's business, management, operations, strategy, or governance. Any such actions will depend upon a variety of factors, including the price and availability of the Common Stock, general market conditions, and other factors deemed relevant by the Reporting Persons. Except as described herein, the Reporting Persons do not currently have any plans or proposals that would relate to or result in any of the actions enumerated in paragraphs (a) through (j) of Item 4 of Schedule 13D.","filing_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-042437.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":86010,"days_to_cover":1.08,"pct_change":-7.53,"settlement_date":"2026-03-31","symbol":"PHGE"},"ai_brief":{"summary":"T3 Defense Inc. files a Schedule 13D on BiomX (PHGE), a clinical-stage phage therapy biotech, with 1.3M shares — notable as the first activist filing on this issuer in 90 days and T3 Defense's first 13D/G on record, suggesting a new strategic relationship rather than a financial play; the defense-sector filer name against a biotech issuer raises questions about a potential pivot, partnership, or a","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T06:22:04.395Z"}},{"accession_number":"0001012975-26-000350","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-10","date_of_event":"2026-04-10","filer_name":"Docler Holding S.a r.l.","filer_cik":"0002044274","issuer_name":"Playboy, Inc.","issuer_cik":"0001803914","issuer_ticker":"PLBY","ticker_source":"insider","cusip":"72814P109","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":14900000,"percent_owned":13.1,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/2044274/0001012975-26-000350.txt","filer_history":null,"issuer_cluster":null,"insider_activity":{"buys":0,"sells":2,"awards_grants":0,"buy_dollars":0,"sell_dollars":50002.856,"unique_insider_count":2,"latest_date":"2026-04-24"},"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":331474,"as_of_period":"2025-12-31"},"short_interest":{"current_short":1581034,"days_to_cover":1.35,"pct_change":4.55,"settlement_date":"2026-03-31","symbol":"PLBY"},"ai_brief":{"summary":"Docler Holding (operator of adult entertainment platforms, a known PLBY strategic partner/investor) filed a 13D/A on a 13.1% stake with no disclosed purpose in the extract — the amendment itself signals a change in intent or ownership terms worth investigating, especially given PLBY's ongoing brand monetization struggles and the absence of any other activist presence in the last 90 days.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:14.236Z"}},{"accession_number":"0001654954-26-003904","form_type":"SCHEDULE 13D","filing_date":"2026-04-24","date_of_event":"2026-04-09","filer_name":"Taylor Paul Richard","filer_cik":"0001746470","issuer_name":"Visium Technologies, Inc.","issuer_cik":"0001082733","issuer_ticker":"VISM","ticker_source":"sec_map","cusip":"92836G309","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":34453488,"percent_owned":3,"purpose":"The Reporting Person acquired the securities in connection with the Issuer's acquisition of 100% of the equity of ConnexUs AI (DE) pursuant to the Stock Purchase Agreement to be executed under the terms of the revised LOI dated March 29, 2026. The transaction includes (i) the Florida ARPRT LLC RAGbox.co IP isolation (Ringfence 2) in which the Reporting Person holds sole manager and 30% membership interest, (iii) the Reporting Person's appointment as CEO and Chairman, and (iv) related governance, capitalization, and GAAP-compliant restructurings. The purpose is to facilitate the acquisition, eliminate legacy dilution overhang, preserve SEC Regulation S-K Item 303/701/703 disclosure integrity, and position the Issuer for post-transaction growth. The Reporting Person has no present plans or proposals to acquire additional securities or to effect any extraordinary corporate transaction except as contemplated by the LOI and Definitive Agreement.","filing_url":"https://www.sec.gov/Archives/edgar/data/1746470/0001654954-26-003904.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":9375,"days_to_cover":1,"pct_change":-87.38,"settlement_date":"2026-03-31","symbol":"VISM"},"ai_brief":{"summary":"Taylor Paul Richard is acquiring a 3% stake in micro-cap VISM (likely sub-$10M market cap given share count math) as part of a reverse-merger-style transaction where his ConnexUs AI entity is being acquired by the issuer, with Richard simultaneously installing himself as CEO and Chairman — classic self-dealing structure in a shell/micro-cap context with 2 prior activist filings in 90 days and near","intent":"board-change","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:18.428Z"}},{"accession_number":"0000921895-26-000972","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-13","date_of_event":"2026-04-09","filer_name":"Stilwell Joseph","filer_cik":"0001113303","issuer_name":"Catalyst Bancorp, Inc.","issuer_cik":"0001849867","issuer_ticker":"CLST","ticker_source":"sec_map","cusip":"14888L101","securities_class":"Common Stock, par value $0.01 per share","shares_owned":348590,"percent_owned":8.6,"purpose":"We intend to seek board representation. Our purpose in acquiring shares of Common Stock of the Issuer is to profit from the appreciation in the market price of the shares of Common Stock through asserting shareholder rights. We do not believe the value of the Issuer's assets is adequately reflected in the current market price of the Issuer's Common Stock. Members of the Group may seek to make additional purchases or sales of shares of Common Stock. Except as described in this filing, no member of the Group has any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of Item 4 of Schedule 13D. Members of the Group may, at any time and from time to time, review or reconsider their positions and formulate plans or proposals with respect thereto. Since 2000, members or affiliates of the Group have taken an 'activist position' in 79 other publicly-traded companies. In each instance, our purpose has been to profit from the appreciation in the market price of the shares we held by asserting shareholder rights. In addition, we believed that the values of the companies' assets were not adequately reflected in the market prices of their shares. Our actions with respect to such publicly-traded companies are described in Schedule A, attached hereto and incorporated herein by reference.","filing_url":"https://www.sec.gov/Archives/edgar/data/1849867/0000921895-26-000972.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":7011,"days_to_cover":1.86,"pct_change":-1.1,"settlement_date":"2026-03-31","symbol":"CLST"},"ai_brief":{"summary":"Stilwell Value — a known community bank activist — explicitly states intent to seek board representation at Catalyst Bancorp (CLST), an 8.6% stake in a thinly-followed mutual-to-stock conversion bank where Stilwell argues NAV is not reflected in the share price; no prior activist presence and zero elite institutional coverage makes this a clean first-mover situation.","intent":"board-change","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:22.563Z"}},{"accession_number":"0000898432-26-000263","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-13","date_of_event":"2026-04-09","filer_name":"Canada Growth Fund Inc.","filer_cik":"0002049820","issuer_name":"Nouveau Monde Graphite Inc.","issuer_cik":"0001649752","issuer_ticker":"NMG","ticker_source":"sec_map","cusip":"66979W842","securities_class":"Common Shares","shares_owned":39682538,"percent_owned":22,"purpose":"Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: CGF entered into a subscription agreement (the Subscription Agreement), dated December 16, 2024, with NMG pursuant to which, on December 20, 2024, CGF purchased, on a private placement basis, 19,841,269 Common Shares of NMG and an additional 19,841,269 Common Shares on exercise of the Warrants, for an aggregate of 39,682,538 Common Shares, for an aggregate subscription price of US$25,000,000 (collectively, the Purchased Shares). This represents approximately 23.1% of the then-outstanding Common Shares, computed on the basis of 152,261,189 Common Shares issued and outstanding as of December 19, 2024, based on information provided by NMG and as reported in the issuers most recent 40-F and 6-K. The Purchased Shares and Warrant Shares (as defined in the Subscription Agreement) were acquired by CGF for investment purposes in the ordinary course of its business. CGF entered into a subscription agreement, dated April 9, 2026 (the April 2026 Subscription Agreement), with NMG, pursuant to which CGF agreed to purchase, on a private placement basis and subject to NMG shareholder approval, 44,452,460 Common Shares of NMG for an aggregate subscription price of US$81,792,526.40 (the 2026 Private Placement Common Shares). This investment represents approximately 27.7% of the then-outstanding Common Shares, calculated based on 160,761,539 Common Shares issued and outstanding as of December 31, 2025, as reported by NMG in its most recent Form 40-F filed with the SEC on March 26, 2026. The Reporting Persons will evaluate their investment in NMG from time to time and may at any time, based on such evaluation, market conditions and other circumstances, increase or decrease their security holdings in NMG or may change their investment strategy as regards to NMG. The Common Shares are listed on the TSX Venture Exchange and the New York Stock Exchange. The Reporting Persons intend to monitor and evaluate the investment on an ongoing basis and expect regularly to review and consider alternative ways of maximizing its return on such investment, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem relevant. The Reporting Persons may engage in discussions with management, the board of directors of NMG, other shareholders of NMG and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of NMG only to the extent such discussions do not create a \"group\" within the meaning of Section 13(d)(3) of the Exchange Act. The Reporting Persons may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements and in compliance with applicable securities laws. The Reporting Persons may from time to time in the future seek to acquire, alone or in conjunction with others, additional Common Shares or other securities issued by NMG through open market purchases, block trades, privately negotiated transactions, tender offer, merger, reorganization or otherwise. The Reporting Persons may also dispose of all or a portion of the securities of NMG, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Common Shares, in each case, subject to limitations under applicable law and any other required approvals. Under the terms of the Investor Rights Agreement, CGF will have certain information and access rights to books and records. CGF has the right to appoint one member of the board and one board observer. CGF has appointed one board observer and intends to nominate one director candidate to stand for election at NMG's 2026 annual general meeting of shareholders. Except as described in this Amendment No. 3, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although the Reporting Persons, at any time and from time to time, may review, reconsider and change its position and/or change its purpose and/or develop such plans and may seek to influence management or the Board with respect to the business and affairs of NMG and may from time to time consider pursuing or proposing such matters with advisors, NMG or other persons.","filing_url":"https://www.sec.gov/Archives/edgar/data/2049820/0000898432-26-000263.txt","filer_history":{"filings_in_window":2,"window_days":90},"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":128190,"as_of_period":"2025-12-31"},"short_interest":{"current_short":1947621,"days_to_cover":2.71,"pct_change":48.43,"settlement_date":"2026-03-31","symbol":"NMG"},"ai_brief":{"summary":"Canada Growth Fund (Canadian federal government-backed fund) completed a $25M private placement in NMG at ~23% ownership via shares + warrants exercised, now filing an amendment likely reflecting the warrant exercise closing on April 9; with 2 activist filings on NMG in the last 90 days and short interest spiking +48% to near 2M shares, this government-backed strategic investor is sitting in a con","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:28.351Z"}},{"accession_number":"0001193125-26-153054","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-13","date_of_event":"2026-04-09","filer_name":"AI Day1 LLC","filer_cik":"0001863302","issuer_name":"Day One Biopharmaceuticals, Inc.","issuer_cik":"0001845337","issuer_ticker":"DAWN","ticker_source":"sec_map","cusip":"23954D109","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":12929322,"percent_owned":12.52,"purpose":"The disclosure in Item 4 is hereby supplemented by adding the following at the end thereof: On April 9, 2026, AI Day1 tendered all of its shares of Common Stock pursuant to the tender offer by Servier Detroit Inc. to purchase all of the issued and outstanding shares of Common Stock for $21.50 per share in cash, upon the terms and subject to the conditions described in the Offer to Purchase and related Letter of Transmittal filed with the SEC on Schedule TO on March 26, 2026.","filing_url":"https://www.sec.gov/Archives/edgar/data/1863302/0001193125-26-153054.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":1455840,"as_of_period":"2025-12-31"},"short_interest":{"current_short":7236832,"days_to_cover":2.22,"pct_change":-10.56,"settlement_date":"2026-03-31","symbol":"DAWN"},"ai_brief":{"summary":"AI Day1 LLC has tendered its entire 12.9M share (12.52%) stake into Servier's $21.50/share cash tender offer for DAWN, filed March 26 — this is a major insider/strategic holder validating the deal by tendering, reducing overhang risk and signaling high deal-close confidence.","intent":"m&a-arb","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:32.778Z"}},{"accession_number":"0001104659-26-042763","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-13","date_of_event":"2026-04-09","filer_name":"Castle Creek Capital Partners VII, LP","filer_cik":"0001746800","issuer_name":"Primis Financial Corp.","issuer_cik":"0001325670","issuer_ticker":"FRST","ticker_source":"sec_map","cusip":"74167B109","securities_class":"Common Stock","shares_owned":1330674,"percent_owned":5.4,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1746800/0001104659-26-042763.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":299329,"as_of_period":"2025-12-31"},"short_interest":{"current_short":249097,"days_to_cover":2.11,"pct_change":-6.05,"settlement_date":"2026-03-31","symbol":"FRST"},"ai_brief":{"summary":"Castle Creek Capital Partners VII, a bank-focused PE firm, filed a 13D/A on community bank Primis Financial (FRST) at 5.4% — the amendment itself signals a change in position or intent from a prior filing, but no explicit purpose was extracted; Castle Creek typically takes active roles in community bank turnarounds, making this worth watching for board or strategic pressure despite the thin disclo","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:37.042Z"}},{"accession_number":"0001104659-26-041986","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-10","date_of_event":"2026-04-09","filer_name":"Growler Mining Tuscaloosa, LLC","filer_cik":"0002101281","issuer_name":"Argo Blockchain Plc","issuer_cik":"0001841675","issuer_ticker":"ARBK","ticker_source":"sec_map","cusip":"040126RR7","securities_class":"Ordinary Shares, nominal value GBP 0.001 per share","shares_owned":28004168880,"percent_owned":88.59,"purpose":"Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following: Subscription Facility Agreement On March 26, 2026, the Issuer entered into a subscription facility agreement (the \"Subscription Facility Agreement\") with Growler, pursuant to which the Issuer may request up to US$5,000,000 in aggregate capital by delivering drawdown notices to Growler during the period ending March 26, 2027. Growler has agreed to fund each requested tranche, subject to the conditions of the Subscription Facility Agreement. Tranches are subject to a minimum of US$500,000 and a maximum of US$1,000,000 each, unless otherwise agreed by Growler in writing. Each drawdown requires: (i) unanimous board approval; (ii) auditor confirmation supporting a going-concern opinion in the relevant accounts; and (iii) representations and warranties of the Issuer true and correct in all material respects. Pricing Mechanism The subscription price per ADS for each tranche equals 100% of the average Nasdaq Official Closing Price of the Issuer's ADSs (Nasdaq: ARBK) over the five (5) trading days ending on the trading day immediately preceding the applicable drawdown notice date (the \"5-Day NOCP\"). Each ADS represents 2,160 Ordinary Shares of (pound)0.001 each. The subscription price is subject to a floor price per ADS and Nasdaq minimum pricing requirements under Listing Rule 5635(d). Initial Tranche On March 26, 2026, the Issuer delivered Drawdown Notice No. 1 to Growler requesting the Initial Tranche of US$2,500,000, which exceeds the standard per-tranche maximum; Growler agreed in writing to fund this above-standard amount as permitted by the Subscription Facility Agreement and also waived the standard 10-Trading Day notice period. The applicable 5-Day NOCP was US$2.948 per ADS (being the average of: US$3.03 on March 16, US$3.01 on March 17, US$2.89 on March 18, US$2.90 on March 19, and US$2.91 on March 20, 2026). At this price, the Initial Tranche results in the issuance of 847,693 Restricted ADSs (representing 1,831,016,880 Ordinary Shares) to Growler, with the Tranche Closing Date (ADS delivery) of April 9, 2026. True-Up Conversion Simultaneously with the Initial Tranche, the Subscription Facility Agreement provides for the conversion into equity of prior payments totaling US$1,259,297.68 made by or on behalf of Growler to or for the account of the Issuer, comprising: (a) US$271,797.68 on December 8, 2025; (b) US$112,500.00 on December 12, 2025; (c) US$775,000.00 on December 22, 2025; and (d) US$100,000.00 on January 15, 2026. The True-Up Payments are converted at the same subscription price as the Initial Tranche (US$2.948 per ADS), resulting in the issuance of 427,170 Restricted ADSs (representing 922,687,200 Ordinary Shares) to Growler. The True-Up Payments do not reduce the remaining availability under the Subscription Facility Agreement. The Ordinary Shares issued in respect of the True-Up Conversion count towards the Exchange Cap described below. Exchange Cap The Subscription Facility Agreement limits the aggregate number of new Ordinary Shares issuable thereunder to 19.99% of the Issuer's outstanding Ordinary Shares as of March 26, 2026, being approximately 5,768,648,865 Ordinary Shares (approximately 2,670,671 ADSs), unless shareholder approval is obtained. Taking into account the 2,753,704,080 Ordinary Shares issued in respect of the Initial Tranche and the True-Up Conversion, approximately 3,014,944,785 Ordinary Shares (approximately 1,395,808 ADSs) remain available under the Exchange Cap. Registration Rights The Subscription Facility Agreement requires the Issuer to file a resale registration statement on Form F-3 covering the Restricted ADSs issued thereunder within 45 days of March 26, 2026 (being on or before May 10, 2026) and to use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable thereafter. Continued Investment Intent Each Reporting Person acquired the securities described in this Amendment in connection with the Subscription Facility Agreement and intends to review its investment in the Issuer on a continuing basis. Each Reporting Person may acquire additional securities of the Issuer pursuant to the Subscription Facility Agreement or otherwise, or may retain or, subject to applicable transfer restrictions under the Amended and Restated Restricted Issuance Agreement with JPMorgan Chase Bank, N.A. as depositary, sell or otherwise dispose of all or a portion of the securities held, at any time and from time to time without prior notice, depending on an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; and other future developments. The Reporting Persons do not currently have any plan or proposal that would result in or relate to any of the transactions or changes enumerated in paragraphs (a) through (j) of","filing_url":"https://www.sec.gov/Archives/edgar/data/1841675/0001104659-26-041986.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":48085,"days_to_cover":3.42,"pct_change":10.06,"settlement_date":"2026-03-31","symbol":"ARBK"},"ai_brief":{"summary":"Growler Mining, holding 88.59% of Argo Blockchain, has extended a $5M subscription facility to the near-insolvent crypto miner with each tranche requiring unanimous board approval and auditor going-concern confirmation — a controlling shareholder acting as lender of last resort to a distressed subsidiary-like entity.","intent":"distressed","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:41.741Z"}},{"accession_number":"0001140361-26-014310","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-10","date_of_event":"2026-04-09","filer_name":"South Dakota Investment Council","filer_cik":"0001538846","issuer_name":"Bristow Group Inc.","issuer_cik":"0001525221","issuer_ticker":"VTOL","ticker_source":"sec_map","cusip":"11040G103","securities_class":"Common Stock","shares_owned":1795920,"percent_owned":6.2,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1525221/0001140361-26-014310.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":346205,"as_of_period":"2025-12-31"},"short_interest":{"current_short":763563,"days_to_cover":4.16,"pct_change":2.99,"settlement_date":"2026-03-31","symbol":"VTOL"},"ai_brief":{"summary":"South Dakota Investment Council, a state pension fund, filed a 13D/A on Bristow Group (VTOL) at 6.2% — unusual for a passive institutional investor to file a 13D rather than 13G, suggesting either a threshold-triggered amendment or an undisclosed agenda; no purpose language was extracted, and this is the filer's first 13D/G activity in 90 days with no insider buying to corroborate activist intent.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:45.601Z"}},{"accession_number":"0000902664-26-001975","form_type":"SCHEDULE 13D","filing_date":"2026-04-13","date_of_event":"2026-04-08","filer_name":"Two Seas Capital LP","filer_cik":"0001823138","issuer_name":"ODYSSEY MARINE EXPLORATION INC","issuer_cik":"0000798528","issuer_ticker":"OMEX","ticker_source":"sec_map","cusip":"676118201","securities_class":"Common Stock, par value $0.0001 per share","shares_owned":5857448,"percent_owned":9.99,"purpose":"The Reporting Persons acquired the securities reported herein for investment purposes in the ordinary course of business. The Reporting Persons acquired such securities because they believed that such securities, when purchased, represented an attractive investment opportunity. On April 8, 2026, the Issuer, Oceanus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer (\"Merger Sub\"), and American Ocean Minerals Corporation, a Delaware corporation (\"AOM,\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") pursuant to which Merger Sub will merge with and into AOM, with AOM surviving the merger and becoming a direct, wholly owned subsidiary of Odyssey (the \"Merger\"). In connection with the Merger Agreement, on April 8, 2026, the Issuer, AOM and TSC entered into a support agreement (the \"Support Agreement\") pursuant to which TSC agreed that at any meeting of the stockholders of the Issuer, it will (a) cause its voting shares of the Issuer to be counted as present thereat for the purpose of establishing a quorum, and (b) vote, or cause to be voted, all of its voting shares of the Issuer, (i) in favor of the Odyssey Share Issuance (as defined in the Merger Agreement), the Odyssey Articles Amendment (as defined in the Merger Agreement), and any other proposal, action, or matter necessary or advisable to consummate the other transactions contemplated by the Merger Agreement, as well as in accordance with other customary provisions. TSC also agreed to customary restrictions on any transfers of voting shares of the Issuer, subject to customary exceptions. The summary of the Support Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Support Agreement, a form of which is attached as Exhibit 99.2 hereto. Global Fund holds (a) warrants to purchase an aggregate of 217,896 shares of Common Stock at a strike price of $1.23 per share that expire on December 1, 2026 (\"Tranche 1 Warrants\"), (b) warrants to purchase an aggregate of 46,544 shares of Common Stock at a strike price of $2.05 per share that expire on December 1, 2026 (\"Tranche 2 Warrants\"), and (c) warrants to purchase an aggregate of 447,761 shares of Common Stock at a strike price of $3.35 per share that expire on December 10, 2027 (the \"Tranche 3 Warrants\", together with the Tranche 1 Warrants and Tranche 2 Warrants, the \"Reported Warrants\"). The Opportunities Fund holds 112,250 Tranche 1 Warrants and 23,997 Tranche 2 Warrants. The foregoing descriptions of the Tranche 1 Warrants, Tranche 2 Warrants, and Tranche 3 Warrants are qualified in their entireties by reference to the full texts of such warrants, the forms of which are included as Exhibit 99.3, Exhibit 99.4, and Exhibit 99.5, respectively, hereto and are incorporated by reference herein. The Reporting Persons have had, and may continue to have, discussions with the Issuer, stockholders or third parties regarding the Issuer's business operations, strategies, capital structure and other matters related to the Issuer, including, without limitation, the terms upon which TSC might support financially the separation of the Issuer's Mexican phosphate asset, PHOSAGMEX. Any of the foregoing discussions may also review options for maximizing shareholder value, enhancing the Issuer's corporate governance, improving capital or asset allocation or various strategic alternatives or operational or management initiatives, including one or more items in subsections (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and may from time to time and at any time in the future depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Board, price levels of the Issuer's securities, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, take such actions with respect to the investment in the Issuer as they deem appropriate. These actions may include: (i) acquiring additional shares of Common Stock and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Issuer (collectively, \"Securities\") in the open market or otherwise; (ii) disposing of any or all of their Securities in the open market or otherwise; (iii) engaging in any hedging or similar transactions with respect to the Securities; or (iv) proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D. Except as set forth herein, the Reporting Persons do not have present plans or proposa","filing_url":"https://www.sec.gov/Archives/edgar/data/798528/0000902664-26-001975.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":2876599,"days_to_cover":1.92,"pct_change":17.53,"settlement_date":"2026-03-31","symbol":"OMEX"},"ai_brief":{"summary":"Two Seas Capital filed a 13D on OMEX the same day the company announced a merger with American Ocean Minerals Corporation, with the stake sized precisely at 9.99% — a threshold-hugging position consistent with an arb or blocking-stake play around the pending deal rather than a passive investment despite the boilerplate 'investment purposes' language.","intent":"m&a-arb","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:49.453Z"}},{"accession_number":"0001012975-26-000352","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-10","date_of_event":"2026-04-08","filer_name":"CapitalSpring Finance Company, LLC","filer_cik":"0001509012","issuer_name":"El Pollo Loco Holdings, Inc.","issuer_cik":"0001606366","issuer_ticker":"LOCO","ticker_source":"sec_map","cusip":"268603107","securities_class":"Common Stock, par value $0.01 per share","shares_owned":1111381,"percent_owned":3.8,"purpose":"Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 5(c) of this Amendment No. 2 is incorporated by reference into this Item 4. The Reporting Persons may, at any time, and subject to compliance with applicable securities laws and regulatory requirements, dispose of or distribute some or all of their remaining Shares of common stock or other securities of the Issuer depending on various factors, including, but not limited to, the price of the Shares, the terms and conditions of the transaction and prevailing market conditions, as well as the liquidity and diversification objectives of the Reporting Persons. Representatives of the Reporting Persons do not currently intend to have additional discussions with the Issuer's management or other third parties regarding the matters discussed in Item 4 of Amendment No. 1 to this Schedule 13D. The Reporting Persons expect to continuously review their investment in the Issuer and may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.","filing_url":"https://www.sec.gov/Archives/edgar/data/1509012/0001012975-26-000352.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":1738144,"days_to_cover":3.52,"pct_change":-13.34,"settlement_date":"2026-03-31","symbol":"LOCO"},"ai_brief":{"summary":"CapitalSpring is signaling an exit from its LOCO position — the amendment explicitly flags potential disposal/distribution of remaining shares and states reps do not currently intend further management discussions, a clear wind-down of prior engagement. At 3.8% and declining (short interest also dropped 13% recently), this is a seller telegraphing the door, not a buyer pressing for change.","intent":"passive","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:29:59.965Z"}},{"accession_number":"0001213900-26-042163","form_type":"SCHEDULE 13D","filing_date":"2026-04-10","date_of_event":"2026-04-08","filer_name":"Kwok Yiu Keung","filer_cik":"0002122644","issuer_name":"K-TECH SOLUTIONS CO LTD","issuer_cik":"0002049187","issuer_ticker":"KMRK","ticker_source":"sec_map","cusip":"G5321F100","securities_class":"Class A Ordinary shares, with par value of US$0.0001 per share","shares_owned":12000000,"percent_owned":72.29,"purpose":"The Reporting Person is pre-IPO shareholder of the Issuer. The Reporting Person holds the shares for investment purposes. Except as set forth herein, the Reporting Person does not have any present plans or proposals which relate to or would result in any of the transactions described in paragraphs (a) through (j) of this Item 4.","filing_url":"https://www.sec.gov/Archives/edgar/data/2049187/0001213900-26-042163.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":1778,"days_to_cover":1,"pct_change":-65.54,"settlement_date":"2026-03-31","symbol":"KMRK"},"ai_brief":{"summary":"Founder/pre-IPO insider filing a 13D on a 72.29% stake in a micro-cap (KMRK) with near-zero institutional ownership, negligible short interest (1,778 shares), and no activist history — this is a routine post-IPO beneficial ownership disclosure with no activist intent signaled.","intent":"passive","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:03.757Z"}},{"accession_number":"0000950103-26-005618","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-10","date_of_event":"2026-04-08","filer_name":"LAUDER AERIN","filer_cik":"0001008090","issuer_name":"ESTEE LAUDER COMPANIES INC","issuer_cik":"0001001250","issuer_ticker":"EL","ticker_source":"sec_map","cusip":"518439104","securities_class":"CLASS A COMMON STOCK PAR VALUE $.01 PER SHARE","shares_owned":19102009,"percent_owned":7.2,"purpose":"The Transfer to RSL Trust occurred on April 8, 2026, and the Change in 4202 Trustee occurred on March 18, 2026, as described in Item 3 of this Amendment. These transactions occurred for estate planning purposes.","filing_url":"https://www.sec.gov/Archives/edgar/data/1001250/0000950103-26-005618.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":96110655,"as_of_period":"2025-12-31"},"short_interest":{"current_short":8172459,"days_to_cover":1.3,"pct_change":-9.98,"settlement_date":"2026-03-31","symbol":"EL"},"ai_brief":{"summary":"Aerin Lauder filing a 13D/A to disclose an intra-family estate planning transfer of her 7.2% Class A stake to the RSL Trust — purely administrative, no change in economic interest or voting control, and no activist agenda signaled.","intent":"passive","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:07.537Z"}},{"accession_number":"0000947871-26-000427","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-10","date_of_event":"2026-04-08","filer_name":"ORBIMED ADVISORS LLC","filer_cik":"0001055951","issuer_name":"Adicet Bio, Inc.","issuer_cik":"0001720580","issuer_ticker":"ACET","ticker_source":"sec_map","cusip":"007002108","securities_class":"Common Stock, par value $0.0001","shares_owned":844787,"percent_owned":8.8,"purpose":"The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer's capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer's business or corporate structure, (g) any change in the Issuer's charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer's securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above.","filing_url":"https://www.sec.gov/Archives/edgar/data/1720580/0000947871-26-000427.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":656546,"days_to_cover":5.95,"pct_change":3.4,"settlement_date":"2026-03-31","symbol":"ACET"},"ai_brief":{"summary":"OrbiMed filed a 13D/A on Adicet Bio (ACET) at 8.8% ownership, but the purpose language is entirely boilerplate — no specific demands, board seats, or strategic agenda disclosed; this reads as a routine amendment to update position size rather than an escalation. Short interest is modest (DTC ~6x) and no other activist presence exists, limiting near-term catalyst visibility.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:12.042Z"}},{"accession_number":"0001193125-26-149161","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-09","date_of_event":"2026-04-08","filer_name":"NIPPON LIFE INSURANCE CO","filer_cik":"0000905591","issuer_name":"Corebridge Financial, Inc.","issuer_cik":"0001889539","issuer_ticker":"CRBD","ticker_source":"sec_map","cusip":"21871X109","securities_class":"Common Stock, par value $0.01 per share","shares_owned":121992454,"percent_owned":26.7,"purpose":"Item 4 is hereby amended and supplemented by the following. VOTING AND SUPPORT AGREEMENT On April 8, 2026, Equitable Holdings, Inc. (\"Equitable\"), the Issuer, and the Reporting Person entered into a voting and support agreement (the \"Voting and Support Agreement\"), in connection with the previously announced Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of March 26, 2026, by and among the Issuer, Equitable, Mountain Holding, Inc., a newly formed Delaware corporation and wholly owned subsidiary of the Issuer (\"HoldCo\"), Palisade Holding, Inc., a newly formed Delaware corporation and a wholly owned subsidiary of HoldCo, and Marcy Holding, Inc., a newly formed Delaware corporation and a wholly owned subsidiary of HoldCo. The Voting and Support Agreement requires that the Reporting Person, subject to certain limited qualifications, vote Covered Stock in favor of, and take certain other actions (or not take certain other actions, as applicable) in furtherance of, the transactions contemplated by the Merger Agreement. As used herein, Covered Stock means the number of shares of Common Stock, par value $0.01 per share, of the Issuer (the \"Common Stock\") that the Reporting Person (a) owns of record and/or beneficially (within the meaning of Rule 13d-3 under the Exchange Act of 1934) on the record date of the Issuer's special stockholder meeting at which the transactions contemplated by the Merger Agreement will be considered and (b) has the right and ability to vote (or to direct the vote of) on the Covered Proposals (as defined in the Voting and Support Agreement) on the record date of such Issuer special stockholder meeting. The Reporting Person has also agreed in the Voting and Support Agreement not to transfer any Covered Stock prior to the approval of the Merger Agreement by the Issuer's stockholders, subject to certain exceptions. The Voting and Support Agreement contains a covenant that obligates the Reporting Person to use its reasonable best efforts to obtain regulatory and governmental approvals in furtherance of the transactions contemplated by the Merger Agreement. In connection therewith, the Reporting Person is obligated to keep the Issuer and Equitable apprised of any substantive communication with regulators and the status of such regulatory and governmental approvals. In addition, the Voting and Support Agreement provides that, at the closing of the transactions contemplated by the Merger Agreement, HoldCo and the Reporting Person will enter into (a) a Stockholder's Agreement (the \"New Stockholder's Agreement\") and (b) a Registration Rights Agreement (the \"New Registration Rights Agreement\"), in each case, substantially in the form attached to the Voting and Support Agreement. Upon the entry into such agreements (as applicable), the Stockholder's Agreement, dated as of December 9, 2024, by and between the Reporting Person and the Issuer (the \"Existing Stockholder's Agreement\") will automatically terminate (in accordance with its terms) and the Registration Rights Assignment Agreement, dated as of December 9, 2024, by and between the Reporting Person, the Issuer and the other parties thereto (the \"Existing Registration Rights Agreement\") will automatically terminate (in accordance with its terms). The terms and conditions of the New Stockholder's Agreement and the New Registration Rights Agreement are substantially similar to the terms of the Existing Stockholder's Agreement and the Existing Registration Rights Agreement, respectively. The Voting and Support Agreement will terminate upon the earlier of the closing of the transactions contemplated by the Merger Agreement, the termination of the Merger Agreement in accordance with its terms and certain other specified events. The foregoing description of the Voting and Support Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement filed as an exhibit to this Schedule 13D, and incorporated herein by reference.","filing_url":"https://www.sec.gov/Archives/edgar/data/1889539/0001193125-26-149161.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":2,"holders":"Point72 Asset Mgmt, Soros Fund Management","total_value_usd":98853484,"as_of_period":"2025-12-31"},"short_interest":{"current_short":31311,"days_to_cover":1,"pct_change":-48.52,"settlement_date":"2026-03-31","symbol":"CRBD"},"ai_brief":{"summary":"Nippon Life (26.7% holder) has entered a Voting and Support Agreement tied to the March 26 merger of Corebridge Financial into Equitable Holdings via a newly formed HoldCo structure — this is a lock-up of the largest single bloc in support of a definitive merger agreement, making the deal outcome heavily dependent on this commitment. Short interest collapsed 48.5% into the March 31 settlement, con","intent":"m&a-arb","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:17.002Z"}},{"accession_number":"0001731122-26-000547","form_type":"SCHEDULE 13D","filing_date":"2026-04-08","date_of_event":"2026-04-08","filer_name":"Galloway Capital Partners, LLC","filer_cik":"0001991451","issuer_name":"Chegg, Inc.","issuer_cik":"0001364954","issuer_ticker":"CHGG","ticker_source":"sec_map","cusip":"163092109","securities_class":"Common Stock, $0.001 par value per share","shares_owned":6093000,"percent_owned":5.44,"purpose":"Each Reporting Person acquired the securities described in this Schedule 13D for investment purposes and intend to review its investment in the Issuer on a continuing basis. Each Reporting Person may from time to time acquire additional securities of the Issuer or retain or sell all or a portion of the shares then held by such Reporting Person, in the open market, block trades, underwritten public offerings or privately negotiated transactions. Any actions any Reporting Person might undertake with respect to its investment in the Issuer may be made at any time and from time to time and will be dependent upon such Reporting Person's review of numerous factors, including, but not limited to: ongoing evaluation of the Issuer's business, financial condition, operations, prospects and strategic alternatives; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; tax considerations; liquidity of the Issuer's securities; and other factors and future developments. Each Reporting Person may consider, explore and/or develop plans and/or make proposals (whether preliminary or final) with respect to, among other things, the Issuer's performance, operations, management, governance (including potential changes to the Board), conflicted party transactions, capital allocation policies, and strategy and plans of the Issuer. Each Reporting Person intends to engage the Board and management with respect to the matters referred to in the preceding sentence. In addition, each Reporting Person may, at any time and from time to time, (i) review or reconsider its position and/or change its purpose and/or formulate plans or proposals with respect thereto and (ii) propose or consider one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D. The Reporting Persons sent the attached letter to management of the Company. The Reporting Persons believe the Company's share price is undervalued and management needs to take steps to improve capital markets communication and investor awareness.","filing_url":"https://www.sec.gov/Archives/edgar/data/1364954/0001731122-26-000547.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":41237,"as_of_period":"2025-12-31"},"short_interest":{"current_short":6049209,"days_to_cover":5.32,"pct_change":-10.18,"settlement_date":"2026-03-31","symbol":"CHGG"},"ai_brief":{"summary":"Galloway Capital Partners initiates a 5.44% stake in Chegg via Schedule 13D — a company whose stock has been in freefall amid AI-driven disruption to its tutoring/homework-help business; the boilerplate 'investment purposes' language and absence of any stated agenda items, combined with this being Galloway's first-ever 13D/G filing on record, leaves intent opaque, though the 13D form choice (vs. 1","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:21.484Z"}},{"accession_number":"0001123292-26-000583","form_type":"SCHEDULE 13D","filing_date":"2026-04-27","date_of_event":"2026-04-07","filer_name":"Emerald Bioventures, LLC","filer_cik":"0002020620","issuer_name":"Galera Therapeutics, Inc.","issuer_cik":"0001563577","issuer_ticker":"GRTX","ticker_source":"sec_map","cusip":"36338D108","securities_class":"Common stock, par value $0.001 per share (the \"Common Stock\")","shares_owned":40216160,"percent_owned":26.5,"purpose":"The response to Item 6 of this Schedule 13D is incorporated herein by reference. Nova Merger On December 30, 2024, the Issuer entered into an Agreement and Plan of Merger (the \"Nova Merger Agreement\"), by and among the Issuer, Grape Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer (\"First Merger Sub\"), Grape Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer (\"Second Merger Sub\") and Nova Pharmaceuticals, Inc., a Delaware corporation (\"Nova\"), on December 30, 2024 (the \"Closing\"), the Issuer acquired Nova. In accordance with the Nova Merger Agreement, First Merger Sub merged with and into Nova (the \"First Merger\"), with Nova surviving as a wholly owned subsidiary of the Issuer. Following the First Merger and as part of the same overall transaction as the First Merger, Nova merged with and into Second Merger Sub (the \"Second Merger\" and, together with the First Merger, the \"Merger\"), with Second Merger Sub being the surviving entity of the Second Merger and renamed Nova Pharmaceuticals Operating, LLC (the \"Surviving Company\"). At the Closing, Emerald acquired 127,000 shares of Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (\"Series B Preferred Stock\"), in exchange for shares of common stock of Nova held immediately prior to the Closing, which were automatically converted into a number of shares of Series B Preferred Stock at an exchange ratio of 177.9117. Pursuant to the Nova Merger Agreement, no earlier than twelve (12) months following the Closing, but no later than eighteen (18) months following the Closing, the Issuer will submit the following matters to its stockholders at a meeting of stockholders (the \"Stockholders' Meeting\") for their consideration: (i) the approval of the conversion of the Series B Preferred Stock into shares of Common Stock (the \"Conversion Proposal\"); (ii) the approval of an amendment to the Issuer's certificate of incorporation to effect a reverse stock split and/or increase the number of authorized shares of Common Stock to such amount as determined by the Issuer's board of directors (the \"Board\") following the Closing; and (iii) the approval of one or more adjournments of the Stockholders' Meeting to solicit additional proxies if there are not sufficient votes cast in favor of the foregoing matters (collectively, the \"Meeting Proposals\"). Following stockholder approval of the Conversion Proposal, each share of Series B Preferred Stock will be convertible into 1,000 shares of Common Stock (the \"Conversion Ratio\") at any time at the option of the holder thereof, subject to certain limitations. The shares of Series B Preferred Stock have no expiration date. On March 17, 2026, the Surviving Company executed a Waiver of Certain Provisions of Agreement and Plan of Merger (the \"Waiver\"). Pursuant to the Waiver, the Surviving Company waived the Issuer's obligations under the Nova Merger Agreement to hold a meeting of stockholders to vote on, among other things, the Conversion Proposal. December 2024 Private Placement Also on December 30, 2024, the Issuer entered into a Securities Purchase Agreement (the \"Purchase Agreement\") with the purchasers named therein (the \"Investors\"), including Emerald. Pursuant to the Purchase Agreement, the Issuer agreed to sell to the Investors an aggregate of 44,111,260 shares of Common Stock and pre-funded warrants (\"Pre-Funded Warrants\") at an aggregate purchase price of $2,885,000 (the \"December 2024 Private Placement\"). In the December 2024 Private Placement, Emerald purchased 3,057,973 shares of Common Stock at $0.0654 per share of Common Stock for an aggregate cost of approximately $199,991. The shares of Common Stock were purchased with cash on hand. The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as an exhibit to this Schedule 13D and is incorporated herein by reference. Partial Mandatory Conversion of Series B Preferred Stock On February 12, 2026, the Issuer filed a Certificate of Amendment (the \"Amendment\") to a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock (the \"Certificate of Designation\") with the Secretary of State of Delaware. The Amendment provides that, in the sole discretion of the Board, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Preferred Stock into a number of shares of Common Stock calculated based on the Conversion Ratio (a \"Mandatory Conversion\"). On April 6, 2026, the Issuer provided Emerald with notice of a partial Mandatory Conversion of Series B Preferred Stock effective April 7, 2026 (the \"Partial Mandatory Conversion\"). In connection with the Partial Mandatory Conversion, 37,158.1873807108 shares of Series B Preferred Stock held by Emerald were converted into 37,158,187 shares of Common ","filing_url":"https://www.sec.gov/Archives/edgar/data/2020620/0001123292-26-000583.txt","filer_history":null,"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":6719,"days_to_cover":1,"pct_change":0,"settlement_date":"2026-03-31","symbol":"GRTX"},"ai_brief":{"summary":"Emerald Bioventures holds 26.5% of GRTX following the December 2024 Nova Pharmaceuticals reverse merger, in which GRTX acquired Nova and issued shares to Nova's former owners — this is a post-merger strategic stake by what appears to be a Nova-side investor now holding a controlling-adjacent position in the combined entity.","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:24.852Z"}},{"accession_number":"0001493152-26-018541","form_type":"SCHEDULE 13D","filing_date":"2026-04-22","date_of_event":"2026-04-07","filer_name":"SPECK MARK R.","filer_cik":"0001792101","issuer_name":"RELIABILITY INCORPORATED","issuer_cik":"0000034285","issuer_ticker":"RLBY","ticker_source":"sec_map","cusip":"759903107","securities_class":"Common Stock of Reliability Incorporated (OTC:RLBY)","shares_owned":3276052,"percent_owned":7.01,"purpose":"The Reporting Person acquired the shares for investment and strategic purposes. The Reporting Person may, in his capacity as an officer of the Issuer, engage in discussions with management and the Board regarding strategic alternatives, including capital raising transactions, potential business combinations, operational initiatives, and other actions intended to enhance shareholder value. The Reporting Person does not currently have any plans or proposals to effect any of the transactions described in clauses (a) through (j) of Item 4 of Schedule 13D, although they may, from time to time, evaluate such alternatives in light of their roles with the Issuer. Depending on market conditions and other factors, the Reporting Person may acquire additional shares or dispose of shares of the Issuer.","filing_url":"https://www.sec.gov/Archives/edgar/data/34285/0001493152-26-018541.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":1,"days_to_cover":1,"pct_change":-99.98,"settlement_date":"2026-03-31","symbol":"RLBY"},"ai_brief":{"summary":"Mark Speck, who is already an officer of Reliability Inc. (RLBY), is filing a 13D on his own employer with a 7% stake — the boilerplate 'strategic alternatives' language is standard but the filer-as-insider dynamic and near-zero short interest (1 share) suggest this is a thinly traded micro-cap with minimal external scrutiny; the filing may be a compliance formality rather than an activist catalys","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:31.522Z"}},{"accession_number":"0001398344-26-006342","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-09","date_of_event":"2026-04-07","filer_name":"Bulldog Investors, LLP","filer_cik":"0001504304","issuer_name":"MFS High Yield Municipal Trust","issuer_cik":"0000809844","issuer_ticker":"CMU","ticker_source":"sec_map","cusip":"59318E102","securities_class":"Common Stock","shares_owned":3072220,"percent_owned":13.55,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1504304/0001398344-26-006342.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":163286,"days_to_cover":3.01,"pct_change":15.43,"settlement_date":"2026-03-31","symbol":"CMU"},"ai_brief":{"summary":"Bulldog Investors, a known closed-end fund activist, holds 13.55% of CMU (MFS High Yield Municipal Trust) — their standard playbook targets CEF discounts via tender offers, open-ending, or board pressure; the 13D form (not 13G) signals active intent despite no explicit purpose disclosed in this extract.","intent":"board-change","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:44.510Z"}},{"accession_number":"0001213900-26-041972","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-09","date_of_event":"2026-04-07","filer_name":"Arts Wing Ltd","filer_cik":"0002095783","issuer_name":"Maase Inc.","issuer_cik":"0001750264","issuer_ticker":"MAAS","ticker_source":"sec_map","cusip":"G4453R115","securities_class":"Class A Ordinary Share, par value $0.09 per share","shares_owned":78564455,"percent_owned":17.77,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/2095783/0001213900-26-041972.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":3579,"days_to_cover":1,"pct_change":-18.34,"settlement_date":"2026-03-31","symbol":"MAAS"},"ai_brief":{"summary":"Amendment to a 13D on a micro/nano-cap (MAAS) with near-zero short interest and no institutional following; filer Arts Wing Ltd has no recent 13D/G history and purpose field is blank, leaving intent entirely opaque — the 17.77% stake is large but there are no corroborating signals of activism, M&A, or board push.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:48.492Z"}},{"accession_number":"0001104659-26-041056","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-08","date_of_event":"2026-04-07","filer_name":"BROOKFIELD Corp /ON/","filer_cik":"0001001085","issuer_name":"Brookfield Business Corp","issuer_cik":"0001654795","issuer_ticker":"BBUC","ticker_source":"sec_map","cusip":"113006100","securities_class":"Class A subordinate voting shares, no par value","shares_owned":142749301,"percent_owned":69,"purpose":"Item 4 of Amendment 1 is hereby amended and restated as follows: On April 8, 2026, BN and Brookfield Wealth Solutions Ltd. (\"BNT\"), a paired entity to BN, completed the transactions pursuant to the previously announced agreement dated March 31, 2026, between BN and BNT. In accordance with the terms of the agreement, a subsidiary of BN transferred 32,991,863 Class A Shares to a subsidiary of BNT for a price of $30.3105 per Class A Share, for an aggregate purchase price of approximately $1,000,000,000 and as consideration, BN received 18,344,438 class C non-voting shares of BNT with the same aggregate value (the \"Class A Share Transfer\"). The per share price of the Class A Shares was based on the 5-day volume weighted average price of the Class A Shares (as reported on the Bloomberg Composite) as of the close of trading on April 7, 2026, net of an all-in discount of 8%. The additional Class A Shares owned by BNT following the Class A Share Transfer are subject to the voting agreement between BN and BNT dated as of March 27, 2026, whereby they have agreed that all decisions to be made with respect to the voting of any Class A Shares held by subsidiaries of BNT will be made jointly by mutual agreement of the applicable BNT subsidiary and BN, other than with respect to any Class A Shares subject to any financing arrangements between the applicable BNT subsidiary and wholly-owned subsidiaries of BN. The foregoing description of the voting agreement in this Item 4 does not purport to be complete and, as such, is qualified in its entirety by reference to such agreement, a copy of which was attached as Exhibit 99.3 to Schedule 13D and incorporated by reference herein.","filing_url":"https://www.sec.gov/Archives/edgar/data/1001085/0001104659-26-041056.txt","filer_history":{"filings_in_window":2,"window_days":90},"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":1769451,"days_to_cover":5.56,"pct_change":-33.01,"settlement_date":"2026-03-31","symbol":"BBUC"},"ai_brief":{"summary":"Brookfield Corp transferred ~33M BBUC Class A shares (~$1B) to affiliated entity Brookfield Wealth Solutions (BNT) at $30.31/share (5-day VWAP), receiving BNT Class C non-voting shares as consideration — an intra-family restructuring that shuffles exposure between paired entities rather than signaling external pressure; BN retains 69% control post-transfer.","intent":"capital-structure","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:52.427Z"}},{"accession_number":"0000807249-26-000040","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-09","date_of_event":"2026-04-06","filer_name":"GAMCO INVESTORS, INC. ET AL","filer_cik":"0000807249","issuer_name":"CORE MOLDING TECHNOLOGIES INC","issuer_cik":"0001026655","issuer_ticker":"CMT","ticker_source":"sec_map","cusip":"218683100","securities_class":"Common Stock","shares_owned":0,"percent_owned":4.1,"purpose":"The Reporting Persons file the long form Schedule 13D pursuant to Section 13d-1 of the Securities Exchange Act of 1934 (the \"Act\") even though they may be technically eligible to file the short form Schedule G. Because the Reporting Persons may regularly communicate with the Issuer's management, filing the Schedule 13D ensures that these conversations are compliant with the reporting obligations under the Exchange Act.","filing_url":"https://www.sec.gov/Archives/edgar/data/1026655/0000807249-26-000040.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":162351,"days_to_cover":4.81,"pct_change":2.86,"settlement_date":"2026-03-31","symbol":"CMT"},"ai_brief":{"summary":"GAMCO filing a 13D on CMT despite 13G eligibility, citing intent to 'regularly communicate with management' — classic Gabelli soft-activist posture; 4.1% stake with no co-filers, no insider activity, and no other institutional presence makes this a lone-wolf engagement play on a micro-cap compounder.","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:30:56.434Z"}},{"accession_number":"0001493152-26-015969","form_type":"SCHEDULE 13D","filing_date":"2026-04-09","date_of_event":"2026-04-06","filer_name":"Davy Joseph P.","filer_cik":"0002003684","issuer_name":"Banzai International, Inc.","issuer_cik":"0001826011","issuer_ticker":"BNZI","ticker_source":"insider","cusip":"06682J308","securities_class":"Class B Common Stock, par value $0.0001 per share","shares_owned":677118,"percent_owned":100,"purpose":"The Reporting Person acquired the securities described herein for compensation and incentive purposes in connection with his role as an executive officer of the Issuer. Except as set forth herein, the Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person may, from time to time, acquire additional securities of the Issuer or dispose of securities of the Issuer in the open market or otherwise, subject to market conditions and other factors.","filing_url":"https://www.sec.gov/Archives/edgar/data/1826011/0001493152-26-015969.txt","filer_history":null,"issuer_cluster":null,"insider_activity":{"buys":0,"sells":0,"awards_grants":1,"buy_dollars":0,"sell_dollars":0,"unique_insider_count":1,"latest_date":"2026-04-06"},"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"BNZI executive Joseph Davy filing a 13D solely to report 677K Class B shares received as compensation — 100% of the Class B float but likely a small slice of total equity given dual-class structure; no activist agenda, no open-market buys, boilerplate purpose language.","intent":"passive","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:00.709Z"}},{"accession_number":"0001193125-26-148545","form_type":"SCHEDULE 13D","filing_date":"2026-04-08","date_of_event":"2026-04-06","filer_name":"LAME JOHN C","filer_cik":"0001080297","issuer_name":"First Internet Bancorp","issuer_cik":"0001562463","issuer_ticker":"INBKZ","ticker_source":"sec_map","cusip":"320557101","securities_class":"Common Stock, without par value","shares_owned":107878,"percent_owned":1.72,"purpose":"The Shares covered by this Schedule 13D were acquired for investment purposes in the ordinary course of business. The Reporting Persons purchased shares based on their belief that the value of the Issuer is in excess of the current market price. The Reporting Persons' investment objective is to profit from appreciation in the market price of the Issuer's voting common stock. Mr. Lame intends to discuss the Issuer's returns for shareholders and the Issuer's strategy for the creation of shareholder value with management, the Issuer's board of directors, and other shareholders of the Issuer. Although the Reporting Persons have no other specific plan or proposal that relates to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, consistent with their investment purpose, the Reporting Persons at any time and from time to time may acquire additional shares of voting common stock or dispose of any or all of the shares of voting common stock depending upon an ongoing evaluation of the investment in the common stock, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Person, and/or other investment considerations.","filing_url":"https://www.sec.gov/Archives/edgar/data/1562463/0001193125-26-148545.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":483600,"as_of_period":"2025-12-31"},"short_interest":{"current_short":1544,"days_to_cover":1.08,"pct_change":19.78,"settlement_date":"2026-03-31","symbol":"INBKZ"},"ai_brief":{"summary":"John Lame files a 13D on First Internet Bancorp (INBKZ) at 1.72% with explicit intent to engage management and board on shareholder returns and strategy — boilerplate value-investor language but the direct mention of board/management dialogue and shareholder value creation signals a soft activist posture; no prior activist presence on this issuer in 90 days and Point72 is the only notable institut","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:07.463Z"}},{"accession_number":"0001193125-26-148276","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-08","date_of_event":"2026-04-06","filer_name":"Carlson Capital, L.P.","filer_cik":"0001056973","issuer_name":"SWK HOLDINGS CORPORATION","issuer_cik":"0001089907","issuer_ticker":"SWKH","ticker_source":"insider","cusip":"78501P203","securities_class":"Common Stock, par value $0.001 per share","shares_owned":0,"percent_owned":0,"purpose":"The information previously provided in response to Item 4 is hereby amended and supplemented by adding the following information: On April 6, 2026, pursuant to the Agreement and Plan of Merger dated as of October 9, 2025 (the \"Merger Agreement\"), Runway Growth Finance Corp. (\"Parent\"), RWAY Portfolio Holding Corp., RWAY Portfolio Corp. (\"Acquisition Sub\"), Runway Growth Capital LLC (\"Adviser\") and SWK Holdings Corporation (\"SWK\") effected a merger pursuant to which SWK was merged with and into Acquisition Sub (the \"First Merger\"). Pursuant to the Merger Agreement, upon completion of the First Merger (the \"Effective Time\"), each issued and outstanding common stock of SWK (\"SWK Common Stock\") was cancelled and converted into the right to receive (i) either (A) 1.7264 shares of common stock, par value $0.01 per share, of Parent (\"Parent Common Stock\" and such consideration, the \"Per Share Stock Consideration\") or (B) $20.59 in cash (the \"Per Share Cash Consideration\") (in each case, based on the election of the holder thereof in accordance with the terms of the Merger Agreement and subject to proration as provided therein) plus (ii) $0.74 in cash, which represents a pro rata share of the guaranteed cash payment paid by the Adviser (the \"Per Share Guaranteed Cash Payment\" and collectively with the Per Share Stock Consideration and the Per Share Cash Consideration, the \"Total Per Share Consideration\"). As a result, the Reporting Persons no longer beneficially own any shares of the Issuer.","filing_url":"https://www.sec.gov/Archives/edgar/data/1056973/0001193125-26-148276.txt","filer_history":null,"issuer_cluster":null,"insider_activity":{"buys":0,"sells":0,"awards_grants":0,"buy_dollars":0,"sell_dollars":0,"unique_insider_count":1,"latest_date":"2026-04-06"},"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"Merger completed April 6, 2026 per the October 2025 agreement — SWK merged into Runway Growth Finance Corp.'s acquisition sub at 1.7264 RWAY shares per SWK share; this 13D/A is a closing update, not a new activist position.","intent":"m&a-arb","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:18.541Z"}},{"accession_number":"0001213900-26-041621","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-08","date_of_event":"2026-04-06","filer_name":"CFAC Holdings V, LLC","filer_cik":"0001828762","issuer_name":"Satellogic Inc.","issuer_cik":"0001874315","issuer_ticker":"SATLW","ticker_source":"sec_map","cusip":"G7823S101","securities_class":"Class A Common Stock, $0.0001 par value","shares_owned":9302809,"percent_owned":7,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1828762/0001213900-26-041621.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":4802,"days_to_cover":1,"pct_change":-14,"settlement_date":"2026-03-31","symbol":"SATLW"},"ai_brief":{"summary":"CFAC Holdings V files an amended 13D on Satellogic (SATLW), a small-cap satellite imagery company, holding 9.3M shares (~7%); amendment with undisclosed purpose from a filer with no recent 13D/G history and zero institutional consensus coverage makes intent opaque, though the 13D form signals active rather than passive positioning.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:21.775Z"}},{"accession_number":"0001085146-26-000306","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-08","date_of_event":"2026-04-06","filer_name":"SYLEBRA CAPITAL LLC","filer_cik":"0002003074","issuer_name":"8X8 INC /DE/","issuer_cik":"0001023731","issuer_ticker":"EGHT","ticker_source":"sec_map","cusip":"282914100","securities_class":"Common Stock","shares_owned":8367394,"percent_owned":6.01,"purpose":"N/A as this was a disposal of securities. The Reporting Persons previously filed a Schedule 13D to report beneficial ownership of the Issuer's Common Stock, reflecting an initial intent to potentially influence the Issuer's management or policies. Subsequently, the Reporting Persons have adopted a passive investment stance but were unable to transition to a Schedule 13G. The Reporting Persons have no plans or proposals with respect to the Issuer that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.","filing_url":"https://www.sec.gov/Archives/edgar/data/1023731/0001085146-26-000306.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":83544,"as_of_period":"2025-12-31"},"short_interest":{"current_short":3777663,"days_to_cover":4.06,"pct_change":25.21,"settlement_date":"2026-03-31","symbol":"EGHT"},"ai_brief":{"summary":"Sylebra is winding down an activist position in 8X8, explicitly stating it has adopted a passive stance but cannot file a 13G (likely due to prior activist intent tainting eligibility), while simultaneously disposing of shares — a clean exit signal with no residual agenda; short interest spiking +25% adds a bearish overlay.","intent":"passive","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:25.166Z"}},{"accession_number":"0001437749-26-011780","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-08","date_of_event":"2026-04-06","filer_name":"BOSTON OMAHA Corp","filer_cik":"0001494582","issuer_name":"Sky Harbour Group Corp","issuer_cik":"0001823587","issuer_ticker":"SKYH-WT","ticker_source":"sec_map","cusip":"83085C107","securities_class":"Class A common stock, par value $0.0001 per share","shares_owned":19059773,"percent_owned":45.6,"purpose":"Item 4 of the Schedule 13D is hereby supplemented as follows: From April 25, 2025 through April 6, 2026, the Reporting Person sold an aggregate of 534,124 shares of Class A Stock at price ranging between $9.05 and $11.99 per share, for total gross proceeds of $5,205,072.59, pursuant to an effective registration statement and under Rule 144 under the Securities Act of 1933, as amended. As a consequence, the Reporting Person's beneficial ownership decreased to 19,059,773 shares of Class A Stock (including the 7,719,779 Warrant Shares). The Reporting Person's beneficial ownership represents 45.56% of the outstanding Class A Stock and 22.72% of the combined voting Common Stock, a decrease primarily caused by such sale by the Reporting Person of 331,500 shares of Class A Stock on April 6, 2026 and additional shares sold during the period from April 25, 2025 through May 30, 2025. A schedule of each such sale transaction by the Reporting Person is attached hereto as Exhibit 4.1.","filing_url":"https://www.sec.gov/Archives/edgar/data/1494582/0001437749-26-011780.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":null,"ai_brief":{"summary":"Boston Omaha is slowly trimming its 45.6% stake in Sky Harbour via open-market sales ($5.2M gross over ~1 year at $9–$12/share), with the latest 331,500-share sale on April 6 triggering this amendment; no strategic agenda change signaled, just a large strategic holder monetizing a position at the margin.","intent":"strategic","confidence":"medium","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:28.708Z"}},{"accession_number":"0000921895-26-000945","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-08","date_of_event":"2026-04-06","filer_name":"Chernett Jorey","filer_cik":"0002042077","issuer_name":"Neuronetics, Inc.","issuer_cik":"0001227636","issuer_ticker":"STIM","ticker_source":"sec_map","cusip":"64131A105","securities_class":"Common Stock, $0.01 par value","shares_owned":9778718,"percent_owned":14.12,"purpose":"Item 4 is hereby amended to add the following: On April 6, 2026, the Reporting Person delivered a letter (the \"Letter\") to the Board of Directors of the Issuer (the \"Board\") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Issuer's transcranial magnetic stimulation (\"TMS\") business. In the Letter, the Reporting Person expressed the view that the Issuer's current structure and strategy are not maximizing shareholder value and that separating or divesting the TMS business should be evaluated as part of a broader strategic review. The Reporting Person also noted that such a transaction could enhance the Issuer's financial flexibility and allow for a more focused strategic direction. The Reporting Person urged the Board to engage qualified investment bankers and immediately commence a formal process to evaluate strategic alternatives. A copy of the Letter is filed as Exhibit 1 to this Amendment No. 1 and is incorporated herein by reference.","filing_url":"https://www.sec.gov/Archives/edgar/data/2042077/0000921895-26-000945.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":9377645,"days_to_cover":3.39,"pct_change":0.21,"settlement_date":"2026-03-31","symbol":"STIM"},"ai_brief":{"summary":"Chernett Jorey, holding 14.12% of STIM, sent a letter to the board on April 6 demanding a strategic alternatives review including a potential sale or divestiture of the core TMS business — a direct operational challenge to management with no prior activist presence on this issuer and no insider buying to suggest internal alignment.","intent":"strategic","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:31.738Z"}},{"accession_number":"0001104659-26-041077","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-08","date_of_event":"2026-04-06","filer_name":"PATRIOT FINANCIAL PARTNERS III, L.P.","filer_cik":"0001703298","issuer_name":"Equity Bancshares, Inc.","issuer_cik":"0001227500","issuer_ticker":"EQBK","ticker_source":"sec_map","cusip":"29460X109","securities_class":"Common Stock","shares_owned":1017214,"percent_owned":4.85,"purpose":"The shares in the Company were acquired and sold for investment purposes. Except as otherwise described herein or in Item 6 below, no member of the Patriot Financial Group III has any plans or proposals that relate to or would result in any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Subject to the limitations imposed by applicable federal and state securities laws, Patriot Financial Group III may further dispose of shares of Common Stock in the Company from time to time, subject to market conditions and other investment considerations, and may cause the Purchased Shares to be distributed in kind to investors. To the extent permitted by applicable bank regulatory limitations, each member of the Patriot Financial Group III may directly or indirectly acquire additional shares of Common Stock or associated rights or securities exercisable for or convertible into Common Stock, depending upon an ongoing evaluation of its investment in the Common Stock, applicable legal restrictions, prevailing market conditions, liquidity requirements of such member of the Patriot Financial Group III and/or investment considerations.","filing_url":"https://www.sec.gov/Archives/edgar/data/1227500/0001104659-26-041077.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":539755,"days_to_cover":4.36,"pct_change":15.42,"settlement_date":"2026-03-31","symbol":"EQBK"},"ai_brief":{"summary":"Patriot Financial Partners III is winding down its EQBK position — the amendment signals active disposal of shares with explicit mention of in-kind distribution to LPs, consistent with a fund nearing end-of-life or rebalancing, not a new activist push. Stake dropped to 4.85% with no board or operational demands; rising short interest (+15.4%) adds a modest headwind context.","intent":"passive","confidence":"high","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:39.097Z"}},{"accession_number":"0001140361-26-013711","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-07","date_of_event":"2026-04-06","filer_name":"DIXON ROBERT E","filer_cik":"0001103016","issuer_name":"MacKenzie Realty Capital, Inc.","issuer_cik":"0001550913","issuer_ticker":"MKZR","ticker_source":"sec_map","cusip":"55453W105","securities_class":"Common Stock, $0.0001 par value per share","shares_owned":146665,"percent_owned":7.46,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1103016/0001140361-26-013711.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":9797,"days_to_cover":1.16,"pct_change":29.23,"settlement_date":"2026-03-31","symbol":"MKZR"},"ai_brief":{"summary":"Dixon files a 13D/A amendment on MKZR, a micro-cap non-traded REIT with virtually no institutional following and negligible short interest (9,797 shares); the amendment itself discloses no stated purpose, and Dixon has no recent 13D/G history, making this look like a small holder updating a position rather than an activist push.","intent":"unclear","confidence":"low","model":"anthropic/claude-sonnet-4.6","generated_at":"2026-04-30T09:31:42.347Z"}},{"accession_number":"0002049820-26-000005","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-06","filer_name":"Canada Growth Fund Inc.","filer_cik":"0002049820","issuer_name":"Nouveau Monde Graphite Inc.","issuer_cik":"0001649752","issuer_ticker":"NMG","ticker_source":"sec_map","cusip":"66979W842","securities_class":"Common shares","shares_owned":39682538,"percent_owned":22,"purpose":"Item 4 of the Schedule 13D is hereby amended and restated in its entirety as follows: CGF entered into a subscription agreement (the Subscription Agreement), dated December 16, 2024, with NMG pursuant to which, on December 20, 2024, CGF purchased, on a private placement basis, 19,841,269 Common Shares of NMG and an additional 19,841,269 Common Shares on exercise of the Warrants, for an aggregate of 39,682,538 Common Shares, for an aggregate subscription price of US$25,000,000 (collectively, the Purchased Shares). This represents approximately 23.1% of the then-outstanding Common Shares, computed on the basis of 152,261,189 Common Shares issued and outstanding as of December 19, 2024, based on information provided by NMG and as reported in the issuers most recent 40-F and 6-K. The Purchased Shares and Warrant Shares (as defined in the Subscription Agreement) were acquired by CGF for investment purposes in the ordinary course of its business. The Reporting Persons will evaluate their investment in NMG from time to time and may at any time, based on such evaluation, market conditions and other circumstances, increase or decrease their security holdings in NMG or may change their investment strategy as regards to NMG. The Common Shares are listed on the TSX Venture Exchange and the New York Stock Exchange. The Reporting Persons intend to monitor and evaluate the investment on an ongoing basis and expect regularly to review and consider alternative ways of maximizing its return on such investment, depending on prevailing market conditions, other investment opportunities, liquidity requirements or other investment considerations the Reporting Persons deem relevant. The Reporting Persons may engage in discussions with management, the board of directors of NMG, other shareholders of NMG and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of NMG only to the extent such discussions do not create a \"group\" within the meaning of Section 13(d)(3) of the Exchange Act. The Reporting Persons may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements and in compliance with applicable securities laws. The Reporting Persons may from time to time in the future seek to acquire, alone or in conjunction with others, additional Common Shares or other securities issued by NMG through open market purchases, block trades, privately negotiated transactions, tender offer, merger, reorganization or otherwise. The Reporting Persons may also dispose of all or a portion of the securities of NMG, in open market or privately negotiated transactions, and/or enter into derivative transactions with institutional counterparties with respect to the Common Shares, in each case, subject to limitations under applicable law and any other required approvals. Under the terms of the Investor Rights Agreement, CGF will have certain information and access rights to books and records. CGF has the right to appoint one member of the board and one board observer. CGF has appointed one board observer and intends to nominate one director candidate to stand for election at NMG's 2026 annual general meeting of shareholders. Except as described in this Amendment No. 2, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although the Reporting Persons, at any time and from time to time, may review, reconsider and change its position and/or change its purpose and/or develop such plans and may seek to influence management or the Board with respect to the business and affairs of NMG and may from time to time consider pursuing or proposing such matters with advisors, NMG or other persons.","filing_url":"https://www.sec.gov/Archives/edgar/data/2049820/0002049820-26-000005.txt","filer_history":{"filings_in_window":2,"window_days":90},"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":128190,"as_of_period":"2025-12-31"},"short_interest":{"current_short":1947621,"days_to_cover":2.71,"pct_change":48.43,"settlement_date":"2026-03-31","symbol":"NMG"},"ai_brief":null},{"accession_number":"0001099910-26-000148","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-06","filer_name":"Kaufman Kapital LLC","filer_cik":"0002033227","issuer_name":"BranchOut Food Inc.","issuer_cik":"0001962481","issuer_ticker":"BOF","ticker_source":"sec_map","cusip":"105230106","securities_class":"Common Stock, $0.001 par value per share","shares_owned":6813306,"percent_owned":34.5,"purpose":"Item 4 of the Schedule 13D is hereby amended and restated in its entirety, and supersedes and replaces in its entirety the Item 4 disclosure in the Original 13D and Amendment No. 1, as follows: June 2025 Warrant Exercise and Amendment. On June 1, 2025, Kaufman Kapital and the Issuer entered into a Warrant Exercise and Amendment to Notes and Warrant Agreement (the \"June 2025 Amendment\"), pursuant to which: (i) Kaufman Kapital agreed to exercise the $1.00 Warrant in full for $1,000,000 cash, (ii) the expiration date of the warrant to purchase 500,000 shares of Common Stock at $1.50 per share (the \"$1.50 Warrant\") was extended from December 31, 2025 to December 31, 2026, (iii) the maturity date of the Convertible Note was extended from December 31, 2025 to December 31, 2026, (iv) the maturity date of the Prior Secured Note was extended to December 31, 2025, and (v) the Issuer agreed not to prepay more than $2,400,000 of principal outstanding under the Convertible Note prior to September 30, 2026 and not to make any prepayment under the Convertible Note while amounts remain outstanding under any non-convertible notes of the Issuer (excluding notes issued pursuant to equipment financing). A copy of the June 2025 Amendment was filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed on June 2, 2025 and is incorporated herein by reference. January 2026 Conversion. On January 28, 2026, Kaufman Kapital converted $500,000 of outstanding principal under the Convertible Note into 659,457 shares of Common Stock at the fixed conversion price of $0.7582 per share. January 2026 New Loan. On January 28, 2026, Kaufman Kapital loaned $1,500,000 to the Issuer pursuant to the New Secured Note. Current Plans and Purposes. The Reporting Persons currently hold the securities of the Issuer for investment purposes. The Reporting Persons continuously evaluate their investment in the Issuer based on a variety of factors, including the Issuer's financial condition, results of operations, business prospects, general market and economic conditions, and other factors. Depending on such evaluation, the Reporting Persons may from time to time acquire additional securities of the Issuer (including through conversion of outstanding Convertible Note principal and accrued interest or exercise of the $1.50 Warrant), dispose of some or all of the securities of the Issuer (including through open-market sales, privately negotiated transactions, block trades, registered offerings, or otherwise), or take any other action with respect to their investment in the Issuer as they may deem appropriate. Any such transactions may be effected at any time and from time to time, without prior notice, and will depend upon a variety of factors, including those described above. Except as otherwise described in this Amendment, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.","filing_url":"https://www.sec.gov/Archives/edgar/data/1962481/0001099910-26-000148.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":72229,"days_to_cover":1.15,"pct_change":3.52,"settlement_date":"2026-03-31","symbol":"BOF"},"ai_brief":null},{"accession_number":"0001337074-26-000004","form_type":"SCHEDULE 13D","filing_date":"2026-04-06","date_of_event":"2026-04-06","filer_name":"He Zhengxu","filer_cik":"0001337074","issuer_name":"Phunware, Inc.","issuer_cik":"0001665300","issuer_ticker":"PHUN","ticker_source":"sec_map","cusip":"71948P209","securities_class":"Common Stock","shares_owned":520000,"percent_owned":2.6,"purpose":"Active investor","filing_url":"https://www.sec.gov/Archives/edgar/data/1337074/0001337074-26-000004.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":816712,"days_to_cover":4.54,"pct_change":15.74,"settlement_date":"2026-03-31","symbol":"PHUN"},"ai_brief":null},{"accession_number":"0000921895-26-000940","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-07","date_of_event":"2026-04-04","filer_name":"Endeavor Blockchain, LLC","filer_cik":"0002101945","issuer_name":"Mawson Infrastructure Group Inc.","issuer_cik":"0001218683","issuer_ticker":"MIGI","ticker_source":"sec_map","cusip":"57778N307","securities_class":"Common Stock, par value $0.001 per share","shares_owned":1500000,"percent_owned":27.5,"purpose":"Item 4 is hereby amended to add the following: On April 4, 2026, the Reporting Persons entered into a cooperation agreement (the \"Cooperation Agreement\") with the Issuer, pursuant to which, the Issuer agreed to accept the resignations of Ryan Costello, Steven Soles and Kathryn Yingling Schellenger (the \"Departing Directors\") from the Issuer's board of directors (the \"Board\"), effective as of April 6, 2026, and to appoint Kyle B. Danges, K. Rodger Davis, Lisa Hough, Cody Smith and Phillip Stanley (the \"New Directors\") to the Board, effective contemporaneously with such resignations. In addition, on April 6, 2026, the Issuer further reconstituted the Board and appointed Joshua Kilgore and Daniel J. Morrison to the Board. In addition, Mr. Kilgore was appointed Executive Chairman of the Board, Mr. Stanley was appointed Chief Executive Officer of the Issuer and Mr. Smith was appointed Chief Operating Officer of the Issuer. Each of the new Board and executive leadership appointments were effective immediately. Pursuant to the Cooperation Agreement, the Reporting Persons and the Issuer also agreed to certain litigation-related provisions, including agreements by the Issuer and the Reporting Persons not to initiate or pursue any legal proceedings against each other and to release each other from any claims except for those arising out of the Cooperation Agreement, as well as certain non-disparagement provisions, which will remain in place from the period beginning on the date of the Cooperation Agreement until the third anniversary thereof (such period, the \"Cooperation Period\"). The Cooperation Agreement will terminate upon the expiration of the Cooperation Period; provided, however, that certain provisions survive termination as set forth therein. The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cooperation Agreement, which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.","filing_url":"https://www.sec.gov/Archives/edgar/data/2101945/0000921895-26-000940.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":62111,"days_to_cover":1,"pct_change":0.92,"settlement_date":"2026-03-31","symbol":"MIGI"},"ai_brief":null},{"accession_number":"0001104659-26-040447","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-07","date_of_event":"2026-04-03","filer_name":"RBCH Ltd","filer_cik":"0002088938","issuer_name":"BRERA HOLDINGS PLC","issuer_cik":"0001939965","issuer_ticker":"SLMT","ticker_source":"sec_map","cusip":"G13311108","securities_class":"Class B Ordinary Shares, $0.05 nominal value per share","shares_owned":22222222,"percent_owned":22.74,"purpose":"Item 4 of the Schedule 13D is supplemented as follows: On March 9, 2026, pursuant to the terms and conditions of the Warrants, RBCH Ltd. provided notice (the \"Increase Notice\") to the Issuer to increase the Beneficial Ownership Limitation limiting the number of Class B Ordinary Shares that RBCH Ltd. can beneficially own from 9.99% to no more than 19.99%, which increase will become effective on May 9, 2026. Upon the effectiveness of the increase of the Beneficial Ownership Limitation, RBCH Ltd. intends to exercise the remaining Pre-Funded Warrants it holds in full to purchase 2,732,123 Class B Ordinary Shares from the Issuer, at a price of $0.05 per Class B Ordinary Share. In connection with the delivery of the Increase Notice, RBCH Ltd. exercised Pre-Funded Warrants to purchase 1,878,988 Class B Ordinary Shares from the Issuer, at a price of $0.05 per Class B Ordinary Share, which exercise was settled by the Issuer on April 3, 2026. Effective April 5, 2026, Viktor Fischer resigned from his position as a member of the Issuer's Board of Directors. The Reporting Persons continue to expect to evaluate on a continuing basis RBCH Ltd.'s goals and objectives and other business opportunities, and may change plans or proposals in the future. In determining from time to time whether to sell the securities reported as beneficially owned in this Schedule 13D (and in what amounts) or to retain such securities, the Reporting Persons will take into consideration such factors as they deem relevant, including the business and prospects of the Issuer, anticipated future developments concerning the Issuer, existing and anticipated market conditions from time to time, general economic conditions, regulatory matters, and other opportunities available to the Reporting Persons. In addition, the Reporting Persons may, from time to time, transfer shares beneficially owned by them for tax, estate or other economic planning purposes. The Reporting Persons may engage in discussions with management, the Board of Directors, other shareholders, and other relevant parties concerning the Issuer's governance, operations, strategy, capital allocation, performance and alternatives to enhance shareholder value. The Reporting Persons reserve the right to exercise the Common Warrants in addition to the Pre-Funded Warrants, dispose of securities of the Issuer or acquire additional securities of the Issuer in the open market, in privately negotiated transactions (which may be with the Issuer or with third parties) or otherwise, to dispose of all or a portion of its holdings of securities of the Issuer.","filing_url":"https://www.sec.gov/Archives/edgar/data/1939965/0001104659-26-040447.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":2497778,"days_to_cover":4.38,"pct_change":-10.43,"settlement_date":"2026-03-31","symbol":"SLMT"},"ai_brief":null},{"accession_number":"0001193125-26-142666","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-03","date_of_event":"2026-04-03","filer_name":"EnCap Partners GP, LLC","filer_cik":"0001726182","issuer_name":"KIMBELL ROYALTY PARTNERS, LP","issuer_cik":"0001657788","issuer_ticker":"KRP","ticker_source":"sec_map","cusip":"49435R102","securities_class":"Common Units Representing Limited Partner Interests","shares_owned":2658422,"percent_owned":4.93,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1726182/0001193125-26-142666.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":2810664,"as_of_period":"2025-12-31"},"short_interest":{"current_short":1169417,"days_to_cover":1.31,"pct_change":-26.46,"settlement_date":"2026-03-31","symbol":"KRP"},"ai_brief":null},{"accession_number":"0001493152-26-015173","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-03","date_of_event":"2026-04-03","filer_name":"Ben Yaackov Yftah","filer_cik":"0002027705","issuer_name":"FEMTO TECHNOLOGIES INC","issuer_cik":"0001888151","issuer_ticker":"FMTOF","ticker_source":"insider","cusip":"31447N303","securities_class":"Common Shares, without par value","shares_owned":290819,"percent_owned":23.24,"purpose":"Shares were issued as part of Reporting Person's compensation as C.E.O of the Company","filing_url":"https://www.sec.gov/Archives/edgar/data/2027705/0001493152-26-015173.txt","filer_history":null,"issuer_cluster":null,"insider_activity":{"buys":0,"sells":0,"awards_grants":1,"buy_dollars":0,"sell_dollars":0,"unique_insider_count":1,"latest_date":"2026-04-08"},"institutional_consensus":null,"short_interest":{"current_short":749,"days_to_cover":3.03,"pct_change":442.75,"settlement_date":"2026-03-31","symbol":"FMTOF"},"ai_brief":null},{"accession_number":"0001104659-26-041551","form_type":"SCHEDULE 13D","filing_date":"2026-04-09","date_of_event":"2026-04-02","filer_name":"RMR Group LLC","filer_cik":"0001613503","issuer_name":"Service Properties Trust","issuer_cik":"0000945394","issuer_ticker":"SVC","ticker_source":"sec_map","cusip":"81761L102","securities_class":"Common Shares of Beneficial Interest, $.01 Par Value","shares_owned":41666666,"percent_owned":6.75,"purpose":"The information set forth in Items 3, 5 and 6 of this Schedule 13D is incorporated herein by reference. In connection with the Offering, also on April 2, 2026, Christopher J. Bilotto, executive vice president of RMR Inc., executive vice president of RMR LLC and one of the Issuer's Managing Trustees and its President and Chief Executive Officer, and Brian E. Donley, senior vice president of RMR LLC and the Issuer's Chief Financial Officer and Treasurer, as well as certain of the Issuer's Trustees, purchased from the underwriters an aggregate of 248,333 Common Shares, including 100,000 Common Shares acquired by Mr. Bilotto, at the public offering price of $1.20 per share. In connection with the Offering, RMR LLC, Messrs. Bilotto, Donley and Portnoy, and certain of the Trustees of the Issuer entered into lock-up agreements with the underwriters, pursuant to which each agreed, without the prior written consent of Yorkville Securities, LLC and subject to certain exceptions, not to sell, transfer or otherwise dispose of any Common Shares beneficially owned by them for a period of 90 days after March 31, 2026, the date of the Underwriting Agreement. The Reporting Persons acquired the Common Shares reported herein for investment purposes. In addition to Mr. Portnoy's role as a Managing Trustee of the Issuer, the Reporting Persons may from time to time engage in discussions with the Issuer, its Trustees and officers, other shareholders of the Issuer and other persons on matters that relate to the management, operations, business, assets, capitalization, financial condition, strategic plans, governance and the future of the Issuer and/or its subsidiaries. The Reporting Persons and their affiliates may acquire or dispose of Common Shares, other shares of capital stock or equity interests of the Issuer and/or its subsidiaries, from time to time, in the open market, private transactions, or otherwise, depending upon various factors, including, without limitation, the Issuer's business, prospects and financial condition, the market for such shares or interests, actions taken by the Issuer's trustees, general economic and stock market conditions, proposals from time to time sought by or presented to them, the existence of any lock-up periods and other factors. Each Reporting Person intends to closely monitor its or his investments and may from time to time take advantage of opportunities presented to it or him. Except as otherwise described above in this Item 4 and with respect to Mr. Portnoy, other than as may have arisen in his capacity as a Trustee of the Issuer or in connection with his role with RMR LLC as a provider of services for or on behalf of the Issuer, the Reporting Persons currently have no plan(s) or proposal(s) that relate to, or would result in, any of the events or transactions described in Item 4 of Schedule 13D, although each Reporting Person may, at any time and from time to time, review or reconsider such Reporting Person's position and/or change such Reporting Person's purpose and/or formulate plans or proposals with respect thereto. To the extent Mr. Portnoy may be involved in the formulation or approval of such plans or proposals as a Trustee of the Issuer or in connection with his role with RMR LLC as a provider of services for or on behalf of the Issuer, Mr. Portnoy does not expect to disclose such developments or his involvement by amending this Schedule 13D unless he also participates in developing or making such plans or proposals in his capacity as an investor in the Issuer.","filing_url":"https://www.sec.gov/Archives/edgar/data/1613503/0001104659-26-041551.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":184000,"as_of_period":"2025-12-31"},"short_interest":{"current_short":9365511,"days_to_cover":3.56,"pct_change":38.7,"settlement_date":"2026-03-31","symbol":"SVC"},"ai_brief":null},{"accession_number":"0001094891-26-000179","form_type":"SCHEDULE 13D","filing_date":"2026-04-09","date_of_event":"2026-04-02","filer_name":"Aklog Lishan","filer_cik":"0001665074","issuer_name":"PAVmed Inc.","issuer_cik":"0001624326","issuer_ticker":"PAVM","ticker_source":"sec_map","cusip":"70387R502","securities_class":"Common Stock, par value $0.001 per share","shares_owned":369068,"percent_owned":5.1,"purpose":"Dr. Aklog acquired beneficial ownership of the shares of Common Stock described in this Schedule 13D for investment purposes. Dr. Aklog may from time to time acquire beneficial ownership of additional securities for investment purposes, or dispose of securities, in the open market or in private transactions, including upon exercise of options described below and subject to the restricted stock agreements described below. At the date of this Schedule 13D, except as set forth in this Schedule 13D, and as consistent with Dr. Aklog's position as Chairman and Chief Executive Officer of the Issuer, Dr. Aklog has no plans or proposals which would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of the board of directors or management of the Issuer; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) Any action similar to any of those actions enumerated above.","filing_url":"https://www.sec.gov/Archives/edgar/data/1665074/0001094891-26-000179.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":23477,"days_to_cover":1.45,"pct_change":0.99,"settlement_date":"2026-03-31","symbol":"PAVM"},"ai_brief":null},{"accession_number":"0000947871-26-000406","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-02","filer_name":"2025 Acquisition Corp","filer_cik":"0002083167","issuer_name":"Forian Inc.","issuer_cik":"0001829280","issuer_ticker":"FORA","ticker_source":"sec_map","cusip":"34630N106","securities_class":"Common Stock, $0.001 par value per share","shares_owned":0,"percent_owned":12.9,"purpose":"The disclosure in Item 4 of the Existing Schedule 13D is hereby amended and supplemented by adding the following at the end thereof: Amendment No. 1 to the Consortium Agreement On April 2, 2026, the Consortium entered into the Amendment No. 1 (the \"Consortium Agreement Amendment\") to the Consortium Agreement (as defined in the Initial 13D), which, among other things, (i) clarifies that the Consortium Agreement remains in full force and effect, notwithstanding any terms therein to the contrary, (ii) provides that the Consortium Agreement will terminate upon the closing of the Merger (as defined below) or a valid termination of the Merger Agreement (as defined below), (iii) imposes certain restrictions to the transfer of Shares prior to such termination (subject to limited permitted transfers to specified transferees who agree to be bound), and (iv) requires each Consortium Member to contribute its Shares to Parent prior to the commencement of the Offer. Merger Agreement Subsequently, on April 2, 2026, the SPV, Bravo Merger Sub, Inc., a Maryland corporation and wholly-owned subsidiary of the SPV (\"Merger Sub\") and Forian entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\"). Pursuant to the Merger Agreement, among other things, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into the Company (the \"Merger\" and, together with the other transactions contemplated by the Merger Agreement, collectively, the \"Transactions\"), and the separate corporate existence of Merger Sub will thereupon cease, and the Company will continue as the surviving corporation and a wholly owned subsidiary of Parent. The Merger will be governed by Section 3-106.1 of the MGCL and will be effected by Merger Sub and Forian without a stockholder vote as soon as practicable following the consummation of the Offer, pursuant to the MGCL. At the effective time of the Merger (the \"Effective Time\"), each Share issued and outstanding immediately prior to the Effective Time (other than Shares (i) held by Forian and its subsidiaries, (ii) owned by the Buyer Parties, or (iii) owned by any direct or indirect wholly owned subsidiary of the Buyer Parties as of immediately prior to the Effective Time, which will be automatically cancelled and extinguished without any conversion thereof or consideration paid therefor), subject to any appraisal rights in accordance with Section 3-202 of the MGCL, will be converted into the right to receive $2.17 in cash per Share, without interest, and subject to deduction for any required tax withholding. Each of the Company, Parent and Merger Sub has made customary representations, warranties and covenants in the Merger Agreement, including relating to (i) the conduct of the Company's business during the interim period, (ii) the efforts of each party to cause the Transactions to be completed and (iii) the preparation and filing of a tender offer statement on Schedule TO and a transaction statement on Schedule 13E-3 by Parent, Merger Sub and the Company and a Schedule 14D-9 by the Company in connection with the Transactions. Completion of the Merger is subject to certain closing conditions, including, but not limited to, (i) that the number of Shares validly tendered and not validly withdrawn, together with the number of Shares then owned beneficially by Parent and Merger Sub (together with their wholly owned subsidiaries), equals at least one share more than fifty percent (50%) of all Shares outstanding as of the consummation of the Offer, (ii) the truth and accuracy of certain representations and warranties of Forian as set forth in the Merger Agreement as of the date of the Merger Agreement and as of the expiration date of the Offer (the \"Expiration Date\") as if made on and as of each such date (as may be subject to materiality, de minimis or other qualifiers), (iii) Forian having performed and complied in all material respects with the covenants, obligations and conditions of the Merger Agreement required to be performed and complied with by Forian at or prior to the Expiration Date, (iv) the non-occurrence of a Company Material Adverse Effect (as defined in the Merger Agreement) on or after the date of the Merger Agreement that is continuing, (v) the non-termination of the Merger Agreement, and (vii) the non-issuance of any judgment, temporary restraining order, preliminary or permanent injunction, or other order from any governmental body of competent jurisdiction preventing the consummation of the Offer or the Merger. Equity Commitment Letter In connection with the Transactions, one of the members of the Consortium, Max Wygod & Emily W Bushnell Co-TTEE Wygod Family Rev LT U/T/A (the \"Sponsor\"), provided an equity commitment letter dated April 2, 2026 (the \"Equity Commitment Letter\"), pursuant to which it committed to provide Parent, on the terms and subject to the c","filing_url":"https://www.sec.gov/Archives/edgar/data/2083167/0000947871-26-000406.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":61144,"days_to_cover":4.55,"pct_change":1.48,"settlement_date":"2026-03-31","symbol":"FORA"},"ai_brief":null},{"accession_number":"0001213900-26-040653","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-02","filer_name":"Cavaghan Andrew","filer_cik":"0002076016","issuer_name":"Blue Gold Ltd","issuer_cik":"0002019435","issuer_ticker":"BGLWW","ticker_source":"sec_map","cusip":"G1331C104","securities_class":"Class A ordinary shares","shares_owned":6431729,"percent_owned":16.9,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/2019435/0001213900-26-040653.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":14145,"days_to_cover":1,"pct_change":41.15,"settlement_date":"2026-03-31","symbol":"BGLWW"},"ai_brief":null},{"accession_number":"0001193125-26-143877","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-02","filer_name":"ADW Capital Partners, L.P.","filer_cik":"0001511001","issuer_name":"COMPASS DIVERSIFIED HOLDINGS","issuer_cik":"0001345126","issuer_ticker":"CODI-PC","ticker_source":"sec_map","cusip":"20451Q104","securities_class":"Shares representing beneficial interests in Compass Diversified Holdings","shares_owned":10500000,"percent_owned":14,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/1511001/0001193125-26-143877.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Soros Fund Management","total_value_usd":599170,"as_of_period":"2025-12-31"},"short_interest":null,"ai_brief":null},{"accession_number":"0000921895-26-000923","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-02","filer_name":"ATG Capital Opportunities Fund LP","filer_cik":"0002079674","issuer_name":"Empery Digital Inc.","issuer_cik":"0001829794","issuer_ticker":"EMPD","ticker_source":"sec_map","cusip":"92864V608","securities_class":"Common Stock, $0.00001 par value per share","shares_owned":4500000,"percent_owned":15.6,"purpose":"Item 4 is hereby amended to add the following: On April 2, 2026, ATG Fund filed a Verified Complaint (the \"Complaint\") in the Court of Chancery of the State of Delaware (the \"Court\"), seeking declaratory and injunctive relief against (i) Co-Chief Executive Officer and Chairman of the Issuer's Board Ryan Lane, Co-Chief Executive Officer and director John Kim, and directors Jonathan P. Foster, Adrian Solgaard, Orn Olason, Rohan Chauhan, Matthew Homer and Ian Read (together, the \"Director Defendants\") and (ii) the Issuer, as nominal defendant (together with the Director Defendants, the \"Defendants\"). The Complaint alleges, among other items, that the Defendant Directors have violated their fiduciary duties to stockholders in connection with the Issuer's (x) entrance into that certain securities purchase agreement dated March 23, 2026 (the \"SPA\") and the issuance of 2,558,422 Shares and 2,079,797 pre-funded warrants thereunder (the \"March Issuance\"), (y) contention that ATG Fund's Nomination Notice of an alternative slate of director candidates was deficient under the Issuer's Third Amended and Restated Bylaws (the \"Bylaws\"), and (z) disclosure to the public regarding the Issuer's alleged rejection of ATG Fund's Nomination Notice. As discussed in detail in the Complaint, ATG Fund believes that the Director Defendants have violated their fiduciary duties to stockholders and the Issuer by adopting unreasonable, entrenchment-driven defensive measures to interfere with the stockholder franchise. ATG Fund is seeking an order from the Court providing the following relief, among other items: o declarations that the Director Defendants have each breached their fiduciary duties of loyalty; o enjoining Defendants from enforcing or relying upon the shareholder rights plan, the accelerated share repurchase program, the March Issuance, or the rejection of ATG Fund's Nomination Notice; o declaring that ATG Fund's Nomination Notice satisfied the Issuer's Bylaws (or, in the alternative, declaring that the nomination period will reopen ahead of the Annual Meeting); o declaring and decreeing that the shares issued in connection with the March Issuance may not vote at the Annual Meeting; o declaring and decreeing that the Director Defendants have each breached their fiduciary duties of disclosure; and o enjoining Defendant's from soliciting proxies until such time as they make corrective disclosures. The foregoing description of the Complaint does not purport to be complete and is qualified in its entirety by reference to the full text of the Complaint, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.","filing_url":"https://www.sec.gov/Archives/edgar/data/2079674/0000921895-26-000923.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":2543781,"days_to_cover":2.62,"pct_change":9.74,"settlement_date":"2026-03-31","symbol":"EMPD"},"ai_brief":null},{"accession_number":"0000897069-26-000818","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-02","filer_name":"AIR T INC","filer_cik":"0000353184","issuer_name":"BLOOMIA HOLDINGS, INC.","issuer_cik":"0000875355","issuer_ticker":"TULP","ticker_source":"sec_map","cusip":"45765Y204","securities_class":"Common Stock, par value of $0.01 per share","shares_owned":1605264,"percent_owned":33.7,"purpose":"The Reporting Persons purchased the Common Stock for investment purposes. The Reporting Persons may in the future acquire additional shares of Common Stock of the Company or dispose of some or all of the shares of Common Stock of the Company held by them in open-market transactions or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable, subject to applicable law. The Reporting Persons may engage in short selling or hedging or similar transactions with respect to the shares of Common Stock, on such terms and at such times as the Reporting Persons may deem advisable, subject to applicable law. On August 15, 2024, the Issuer entered into a Delayed Draw Term Note with Air T in the principal amount of $2.500,000. Pursuant to the terms of the Note, the Issuer may request from time to time prior to August 15, 2026, and Air T, may make one or more loans. The loans are solely to be used to (i) fund the operations and growth of the Issuer's business and (ii) pay transaction fees and expenses related to the note. The entire principal amount outstanding on the loans, together with accrued and unpaid interest thereon is due and payable in full on the earlier of (i) August 15, 2029, (ii) Issuer's receipt of a written demand by Air T delivered on or after February 15, 2026. and (iii) such earlier date as all principal owing thereunder becomes due and payable by acceleration or otherwise (the \"Maturity Date\"). The Borrower may prepay any loan outstanding, together with accrued and unpaid interest on such loan, at any time without prepayment or penalty and amounts paid or prepaid in respect of any loan may not be reborrowed. Each loan made under the note bears interest, beginning on the date such loan is advanced by the Air T to the Issuer, at a rate per annum equal to 8% as of the date of each loan. All accrued and unpaid interest on the loans is due and payable by the Borrower on the Maturity Date; provided that any default interest due under the loan is payable on demand. The obligations of the Issuer under this note rank and shall continue to rank at least senior in priority of payment to all subordinated indebtedness and all senior unsecured indebtedness of the Issuer. On September 27, 2024, the Issuer entered into an Amended and Restated Delayed Draw Term Note with Air T (the \"Amended Note\"). The Amended Note amends, restates, replaces and supersedes the prior Delayed Draw Term Note, dated as of August 15, 2024. The terms of the Amended Note remain essentially the same as the prior Delayed Draw Term Note except that the principal amount of the note was increased to $3,500,000. On September 15, 2025, the Issuer entered into a Promissory Note with AO Partners I, L.P. pursuant to which AO Partners I lent $1,699,844 to the Issuer. The Note has a maturity date of June 1, 2027, and bears interest at a rate per annum equal to 13.5%. Under the Note, the Issuer may enter into other Promissory Notes with other parties on the same terms (all of the Promissory notes entered into are referred to herein as \"Pari Passu Notes\"), and the Note provides that until all amounts outstanding under the Pari Passu Notes have been paid in full, the lenders may appoint one individual as a non-voting observer to the Issuer's board of directors. A copy of the Promissory Note is attached as Exhibit 99.3 to this filing, and is incorporated herein by reference. On September 15, 2025, the Issuer entered into a Promissory Note with Air T, Inc. pursuant to which Air T lent $1,100,156 to the Issuer. The Note has a maturity date of June 1, 2027, and bears interest at a rate per annum equal to 13.5%. Under the Note, the Issuer may enter into other Promissory Notes with other parties on the same terms (all of the Promissory notes entered into are referred to herein as \"Pari Passu Notes\"), and the Note provides that until all amounts outstanding under the Pari Passu Notes have been paid in full, the lenders may appoint one individual as a non-voting observer to the Issuer's board of directors. A copy of the Promissory Note is attached as Exhibit 99.4 to this filing, and is incorporated herein by reference. The Reporting Person acquired shares of the Issuer in connection with its participation in the Issuer's rights offering that commenced in February 2026 and expired on April 1, 2026. The Reporting Person received non-transferable subscription rights as a stockholder of record and exercised such rights, including, where applicable, the over-subscription privilege, to purchase shares of common stock at a subscription price of $4.05 per share. In connection with the rights offering, all of the above referenced loans were converted into shares of the Issuer. To the extent the actions described herein may be deemed to constitute a \"control purpose\" with respect to the Securities Exchange Act of 1934, as amended, and the regulations thereunder. the Reporting Persons have such a purpose. Except as noted i","filing_url":"https://www.sec.gov/Archives/edgar/data/353184/0000897069-26-000818.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":null,"short_interest":{"current_short":17522,"days_to_cover":17.3,"pct_change":13.32,"settlement_date":"2026-03-31","symbol":"TULP"},"ai_brief":null},{"accession_number":"0000070858-26-000217","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-02","filer_name":"BANK OF AMERICA CORP /DE/","filer_cik":"0000070858","issuer_name":"Federated Hermes Premier Municipal Income Fund","issuer_cik":"0001199004","issuer_ticker":"FMN","ticker_source":"insider","cusip":"31423P504","securities_class":"Variable Municipal Term Preferred Shares","shares_owned":1147,"percent_owned":100,"purpose":null,"filing_url":"https://www.sec.gov/Archives/edgar/data/70858/0000070858-26-000217.txt","filer_history":null,"issuer_cluster":null,"insider_activity":{"buys":0,"sells":0,"awards_grants":0,"buy_dollars":0,"sell_dollars":0,"unique_insider_count":1,"latest_date":"2026-04-02"},"institutional_consensus":null,"short_interest":{"current_short":19785,"days_to_cover":1,"pct_change":49.35,"settlement_date":"2026-03-31","symbol":"FMN"},"ai_brief":null},{"accession_number":"0001104659-26-040053","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-06","date_of_event":"2026-04-02","filer_name":"LUMINUS MANAGEMENT LLC","filer_cik":"0001279151","issuer_name":"BATTALION OIL CORP","issuer_cik":"0001282648","issuer_ticker":"BATL","ticker_source":"insider","cusip":"07134L107","securities_class":"Common Stock","shares_owned":14132184,"percent_owned":43.4,"purpose":"As previously disclosed, on March 24, 2026, the Master Fund effected a distribution in kind of 5,200,000 shares (the \"Shares\") of common stock of the Issuer in the aggregate to: (i) its two feeder funds, Luminus Energy Partners QP, LP, a Delaware limited partnership (\"LEP Onshore\"), which received 2,117,138 Shares, and LEP Offshore (through LILP, an intermediary entity which received 2,641,190 Shares); and (ii) two affiliates that have economic interests in the Master Fund, namely LCP Onshore, which received 391,694 Shares, and LCP Offshore, which received 91,930 Shares. Each of the Funds had issued illiquid certificates to their respective investors on April 1, 2020. In connection with the distribution in kind, the Manager planned to distribute 5,200,000 shares of common stock. As Certificate Holders entitled to receive 1,145,542 shares of common stock (the \"Segregated Shares\") in the aggregate did not either (i) respond or provide the requisite information to the Fund's administrator and the Manager to receive the Segregated Shares, (ii) were unable to accept delivery of the Segregated Shares or (iii) chose not to participate in the distribution (such Certificate Holders being referred to as the \"Non Returners\"), the Master Fund continues to hold the Segregated Shares and retains both voting and disposition power over the Segregated Shares. The Master Fund, however, has no economic interest in the Segregated Shares as the Master Fund is holding the Segregated Shares for the benefit of the Non Returners. On April 2, 2026, the Master Fund distributed 379,559 shares of common stock to certain Non Returners who provided their information. The Master Fund can, in its discretion, sell the remaining Segregated Shares on behalf of the Non Returners and/or make one or more distribution in kind of the remaining Segregated Shares to the Non Returners who provide their requisite information.","filing_url":"https://www.sec.gov/Archives/edgar/data/1282648/0001104659-26-040053.txt","filer_history":{"filings_in_window":2,"window_days":90},"issuer_cluster":{"filings_in_window":2,"window_days":90},"insider_activity":{"buys":0,"sells":0,"awards_grants":0,"buy_dollars":0,"sell_dollars":0,"unique_insider_count":1,"latest_date":"2026-04-02"},"institutional_consensus":null,"short_interest":{"current_short":2786237,"days_to_cover":1,"pct_change":124.75,"settlement_date":"2026-03-31","symbol":"BATL"},"ai_brief":null},{"accession_number":"0000902664-26-001872","form_type":"SCHEDULE 13D/A","filing_date":"2026-04-03","date_of_event":"2026-04-02","filer_name":"Elliott Investment Management L.P.","filer_cik":"0001791786","issuer_name":"SOUTHWEST AIRLINES CO","issuer_cik":"0000092380","issuer_ticker":"LUV","ticker_source":"sec_map","cusip":"844741108","securities_class":"Common Stock, par value $1.00 per share","shares_owned":24308000,"percent_owned":4.9,"purpose":"The Reporting Person reduced the economic exposure of the Elliott Funds for portfolio management purposes. The Elliott Funds remain significant shareholders of the Issuer based on the Reporting Person's confidence that the Issuer's execution of ongoing strategic initiatives will translate to greater profitability, accretive capital-allocation opportunities and shareholder value creation.","filing_url":"https://www.sec.gov/Archives/edgar/data/1791786/0000902664-26-001872.txt","filer_history":null,"issuer_cluster":null,"insider_activity":null,"institutional_consensus":{"holder_count":1,"holders":"Point72 Asset Mgmt","total_value_usd":14382840,"as_of_period":"2025-12-31"},"short_interest":{"current_short":20445702,"days_to_cover":2.41,"pct_change":-9.04,"settlement_date":"2026-03-31","symbol":"LUV"},"ai_brief":null}]}